GIP/GLP-1Approved 2022

Tirzepatide

Last updated

Dual GIP and GLP-1 receptor agonist. Once weekly.

Mounjaro, Zepbound·Eli Lilly

Tirzepatide: lowest prices now

  • Lowest FDA-approved

    LillyDirect (Eli Lilly)

    $299-$449/28 days · about $320 per 30 days

  • Lowest compounded on a monthly plan, not FDA-approved

    Collective

    $69/mo + $199/yr membership · about $86 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before

Catalog reviewed Nov 4, 2026. Feed checks and price reviews are dated separately below. How we verify. Not medical advice.

Data updated . What changed

Average weight lost in its trials

  • 15 mg weekly (Zepbound)SURMOUNT-1 · 72 wks
    −20.9% (nejm.org/doi/full/10.1056/NEJMoa2206038) (-20.9% at 72 wks · SURMOUNT-1 · 15 mg weekly (Zepbound))about 42 lb at 200 lb

Averages from separate trials, so they are not a head-to-head ranking and not a prediction. Pounds apply the percentage to a 200 lb starting weight.

What the FDA label says

  • Zepbound injectionWeight management in adults with obesity, or overweight with a weight-related condition; moderate to severe obstructive sleep apnea in adults with obesity. FDA label (pi.lilly.com)
Information from FDA labels and published trials, not medical advice.

What to know about Tirzepatide

An ingredient can have several brands, formulations, and approved uses. Prices and trial findings belong to the specific product and dose shown.

Sourced starting quote

$299/28 days (pharmacy.amazon.com/ZEPBOUND-KWIKPEN-2-5-MG-DOSE-PEN-INJ/dp/B0GP27N9T3)

28-day supply (pharmacy.amazon.com)

≈ $320.36 per 30 days at this quoted rate

Offer through

Checked on pharmacy.amazon.com

Zepbound KwikPen via Amazon Pharmacy

Amazon Pharmacy · without insurance, 2.5 mg; includes the manufacturer coupon if eligible (list price $498.98); prescription required

Price conditions

without insurance, 2.5 mg; includes the manufacturer coupon if eligible (list price $498.98); prescription required

The 7.5 mg KwikPen is also $449. Amazon fills a prescription you already have and delivers in all 50 states. FDA-approved product.

28-day supply

Quote at the cited trial dose

$449/28 days (pharmacy.amazon.com/ZEPBOUND-KWIKPEN-15-MG-DOSE-PEN-INJ/dp/B0GP1V2X9V)

28-day supply (pharmacy.amazon.com)

≈ $481.07 per 30 days at this quoted rate

Offer through

Checked on pharmacy.amazon.com

Zepbound KwikPen via Amazon Pharmacy · 15 mg

Amazon Pharmacy · without insurance, 2.5 mg; includes the manufacturer coupon if eligible (list price $498.98); prescription required

Price conditions

without insurance, with Lilly's self-pay card, which ends 12/31/2026 and requires each refill within 45 days of the previous delivery, as Lilly's Zepbound savings page states (otherwise Lilly's regular $699); 15 mg; includes the manufacturer coupon if eligible (list price $699)

The 7.5 mg KwikPen is also $449. Amazon fills a prescription you already have and delivers in all 50 states. FDA-approved product.

28-day supply

FDA-approved offers only in this summary. Starting and trial-dose quotes may cover different products. Every cash quote was checked on or after . Confirm eligibility, dose, fees, and supply length with the provider.

Mean weight change in the cited trial
−20.9% (nejm.org/doi/full/10.1056/NEJMoa2206038) (-20.9% at 72 wks · SURMOUNT-1 · 15 mg weekly (Zepbound))

SURMOUNT-1 · 15 mg weekly (Zepbound)

A1c reduction in the cited trial
−2.3 pp (investor.lilly.com/news-releases/news-release-details/lillys-surpass-2-results-published-new-england-journal-medicine) (-2.3% at 40 wks · SURPASS-2 · HbA1c change in percentage points)

SURPASS-2

Stopped treatment for adverse events
6.2% (nejm.org/doi/full/10.1056/NEJMoa2206038) (6.2% vs 2.6% placebo (15 mg) · SURMOUNT-1 (15 mg, 72 wks, obesity))

SURMOUNT-1 (15 mg, 72 wks, obesity)

FDA shortage report
No shortage reported

No matching shortage record was returned in the latest complete FDA check.

Route & frequency
Once weekly

Trial averages are not personal predictions. Weight-loss, A1c, and side-effect figures may come from different trials, doses, or populations; follow each source for its context.

Where to get it

Ways to get Tirzepatide

Compare sourced starting and maintenance-dose prices. Compounded products and membership fees are labeled separately.

592 current prices

  • View
    $69/mo + $199/yr membership (collective.org)

    about $86 a month over a year with the membership

    Checked on collective.org

    Top dose: same price at 15 mg

    Terms & source

    Advertised price: medication billed monthly, cancel anytime, the same price at any dose, plus a required $199 annual membership after a 21-day free trial

    Billed per month; days of supply not on record, so ordered as four weekly doses.

    Top-dose terms: The seller states one price at every dose, so this is also its price at 15 mg.

    Collective says "Same price, any dose" and "Cancel anytime". Its membership is required for every medication: "$199 /year, billed annually", after a 21-day free trial. Run by Health for Everyone Inc. d/b/a CollectiveOS; not sold in AL, CA, LA, MA, MS or WA. Compounded products are not FDA-approved.

    Partner: This seller may pay us a referral fee if you buy through our link, at no extra cost to you. That moves it up in our default order, never in a lowest-cost sort, and is not a medical recommendation.

    Confirm the prescribed dose, supply length, membership or consultation fees, and refill conditions with the seller. A listed offer does not confirm eligibility or stock.

    Advertised price as read on its own page (collective.org)
  • View
    $129/mo (eden.health/glp-1/tirzepatide)

    Checked on eden.health

    Top dose: same price at 15 mg

    Terms & source

    Advertised price: one price at every dose; no membership fee; no introductory rate

    Billed per month; days of supply not on record, so ordered as four weekly doses.

    Top-dose terms: The seller states one price at every dose, so this is also its price at 15 mg.

    One flat monthly price at every dose, including doctor-guided care and free expedited shipping. No annual or long-term plan required. Compounded; not FDA-approved.

    Partner: This seller may pay us a referral fee if you buy through our link, at no extra cost to you. That moves it up in our default order, never in a lowest-cost sort, and is not a medical recommendation.

    Confirm the prescribed dose, supply length, membership or consultation fees, and refill conditions with the seller. A listed offer does not confirm eligibility or stock.

    Advertised price as read on its own page (eden.health)
  • View
    from $89/mo (nuimagemedical.com/tirzepatide)

    6-month plan

    Checked on nuimagemedical.com

    Top dose: No separate price on record

    Terms & source

    Advertised price: "Tirzepatide Injections As low as $89/mo 6-month supply"; also "weekly injection from $89/month"

    The monthly figure of a 6-month plan; days of supply not on record, so ordered as four weekly doses.

    The same $89 starting figure as its semaglutide page, on a 6-month supply; the dose it covers is not stated, so a careful editor should treat it as a floor. Tirzepatide tablets are also sold from $89/mo on a 5-month supply (not listed). Compounded; not FDA-approved.

    Partner: This seller may pay us a referral fee if you buy through our link, at no extra cost to you. That moves it up in our default order, never in a lowest-cost sort, and is not a medical recommendation.

    Confirm the prescribed dose, supply length, membership or consultation fees, and refill conditions with the seller. A listed offer does not confirm eligibility or stock.

    Advertised price as read on its own page (nuimagemedical.com)
  • View
    from $89/mo (nuimagemedical.com/tirzepatide)

    5-month plan

    Checked on nuimagemedical.com

    Top dose: No separate price on record

    Terms & source

    Advertised price: "Tirzepatide RDT Rapid-dissolve tablets As low as $89/mo 5-month supply"; also "a daily tablet"

    The monthly figure of a 5-month plan; days of supply not on record, so ordered as four weekly doses.

    The figure is a starting price on a 5-month supply; the dose it covers is not stated, so treat it as a floor. The page says "compounded tirzepatide is not FDA-approved". Compounded; not FDA-approved.

    Partner: This seller may pay us a referral fee if you buy through our link, at no extra cost to you. That moves it up in our default order, never in a lowest-cost sort, and is not a medical recommendation.

    Confirm the prescribed dose, supply length, membership or consultation fees, and refill conditions with the seller. A listed offer does not confirm eligibility or stock.

    Advertised price as read on its own page (nuimagemedical.com)
  • View
    from $99/mo (galaglp1.com/weight-loss/compounded-tirzepatide)

    12-month plan

    Checked on galaglp1.com

    Top dose: No separate price on record

    Terms & source

    Advertised price: annual plan, billed once a year ("From $99/month Annual plan, billed once a year"); "Your exact price depends on your state, your dose and the plan you choose, and you see it before you pay."; provider visit and shipping included

    The monthly figure of a 12-month plan; days of supply not on record, so ordered as four weekly doses.

    Gala's tirzepatide page: "compounded tirzepatide starts at $99 per month on the annual plan, billed once a year" (read 11 Nov 2026; its product page said from $179 a month on 9 Nov). Its weight-loss page: "Tirzepatide from $99/mo". No month-to-month price is published. Its weight-loss page and homepage say a higher dose costs nothing more, while both product pages (read 12 Nov 2026) say the price depends on the dose, so no price at the full dose is stated here. Cancel anytime, per its compounded GLP-1 page. Compounded; not FDA-approved.

    Partner: This seller may pay us a referral fee if you buy through our link, at no extra cost to you. That moves it up in our default order, never in a lowest-cost sort, and is not a medical recommendation.

    Confirm the prescribed dose, supply length, membership or consultation fees, and refill conditions with the seller. A listed offer does not confirm eligibility or stock.

    Advertised price as read on its own page (galaglp1.com)
  • View
    $83/mo (weightrx.com/tirzepatide-83)

    12-month plan

    $997 paid upfront, 12-month minimum

    Checked on weightrx.com

    Top dose: No separate price on record

    Terms & source

    Advertised price: its offer page reads "/month for 12 months" and "$997 billed once · 12-month price lock", with "Monthly check-ins with a board-certified doctor" and "Free shipping every month"; the page's banner is "Limited Time Offer" and it lists "Higher-dose fee ($99/mo) waived for 3 months"

    $997 paid upfront, 12-month minimum (weightrx.com)

    The monthly figure of a 12-month plan; days of supply not on record, so ordered as four weekly doses.

    Its homepage says "Compounded Tirzepatide for as low as $83/mo" and "Starts at $83/mo" without naming the plan; this offer page says the $83 is a 12-month plan billed once. The page names no shorter plan, carries a "Limited Time Offer" countdown, and adds a "Higher-dose fee ($99/mo)" that is waived only for the first 3 months. Compounded; not FDA-approved.

    Confirm the prescribed dose, supply length, membership or consultation fees, and refill conditions with the seller. A listed offer does not confirm eligibility or stock.

    Advertised price as read on its own page (weightrx.com)
  • View
    $120/mo (maxlife.com/compounded-tirzepatide)

    Checked on maxlife.com

    Top dose: same price at 15 mg

    Terms & source

    Advertised price: "Flat $120/mo*" ("*All-inclusive, same price at every dose"); its own comparison page says "Billed month to month, MaxLife's $120/mo flat is lower than the other month-to-month prices in our table"; "Your prescription ships every 3 months (90 days)."; "No insurance, no membership fee and no hidden fees."

    Billed per month; days of supply not on record, so ordered as four weekly doses.

    Top-dose terms: The seller states one price at every dose, so this is also its price at 15 mg.

    The order page itself says only "Flat $120/mo*"; the month-to-month billing is from MaxLife's own comparison pages (best-tirzepatide-providers-in-washington and others, read 2026-11-14). Shipping is every 3 months while the price is a month. Compounded; not FDA-approved.

    Partner: This seller may pay us a referral fee if you buy through our link, at no extra cost to you. That moves it up in our default order, never in a lowest-cost sort, and is not a medical recommendation.

    Confirm the prescribed dose, supply length, membership or consultation fees, and refill conditions with the seller. A listed offer does not confirm eligibility or stock.

    Advertised price as read on its own page (maxlife.com)
  • View
    $149/4 weeks (healthyliving.clinic/trust)

    3-month plan

    ≈ $159.64 per 30 days

    Checked on healthyliving.clinic

    Top dose:$199/mo (healthyliving.clinic/trust)at 15 mg

    Checked on healthyliving.clinic

    Terms & source

    Advertised price: a 12-week box at 3 to 9 mg a week, paid in 3 payments of $149, one every 4 weeks, all 3 due once the box ships; the ongoing price, not an introductory one; physician visit, medication, syringes and shipping included, no membership, consult, shipping or annual fee

    28-day supply (healthyliving.clinic)

    ≈ $159.64 per 30 days at this quoted rate

    Top-dose terms: The clinic's price table states $199 a month above 9 mg, and its standard-dose page prices every weekly dose above 9 mg the same.

    Priced by weekly dose: $99 every 4 weeks at 1.5 to 2 mg (sold as a microdosing plan), $149 every 4 weeks at 3 to 9 mg, and $199 a month above 9 mg. Cancel at least 5 days before the next box is billed; full refund if the doctor does not approve. Prescribed by U.S. physicians and filled by NewLife or Greenwich, state-licensed compounding pharmacies; all 50 states. Compounded; not FDA-approved.

    Partner: This seller may pay us a referral fee if you buy through our link, at no extra cost to you. That moves it up in our default order, never in a lowest-cost sort, and is not a medical recommendation.

    Confirm the prescribed dose, supply length, membership or consultation fees, and refill conditions with the seller. A listed offer does not confirm eligibility or stock.

    Advertised price as read on its own page (healthyliving.clinic)
  • View
    $126/mo (mondae.com/treatments/compounded-tirzepatide)

    Checked on mondae.com

    Top dose: same price at 15 mg

    Terms & source

    Advertised price: per month on the 1-month plan ("Plan length: 1 month 3 months 6 months", the 1-month plan selected), the same price at every dose, no membership fees

    Billed per month; days of supply not on record, so ordered as four weekly doses.

    Top-dose terms: The seller states one price at every dose, so this is also its price at 15 mg.

    Mondae says "No membership fees" and "Same price every dose". Its product page shows this price with its 1-month plan selected, beside tabs for 3 and 6 months; its homepage says from $69 and from $114, the longer plans' prices. Compounded products are not FDA-approved.

    Partner: This seller may pay us a referral fee if you buy through our link, at no extra cost to you. That moves it up in our default order, never in a lowest-cost sort, and is not a medical recommendation.

    Confirm the prescribed dose, supply length, membership or consultation fees, and refill conditions with the seller. A listed offer does not confirm eligibility or stock.

    Advertised price as read on its own page (mondae.com)
  • View
    $129/mo (joinem.co/pages/terms-conditions)

    Checked on joinem.co

    Top dose: same price at 15 mg

    Terms & source

    Advertised price: its terms page, "Tirzepatide Injections": "Monthly: $129/month", "3-month bundle: $126/month", "6-month bundle: $123/month", "12-month bundle: $99/month"; "Includes all doses, shipping and provider visits."; "Charges will continue until you cancel your subscription"; its FAQ: "Your price does not increase if your dose changes within the same medication."

    Billed per month; days of supply not on record, so ordered as four weekly doses.

    Other plan lengths

    • $126/mo on 3 months
    • $123/mo on 6 months
    • $99/mo on 12 months

    Top-dose terms: The seller states one price at every dose, so this is also its price at 15 mg.

    Its homepage shows "flat rate at" "$99/month" under "Pre-Black Friday Sale Promo Applied. Save $200 instantly" without naming a plan; that figure equals the 12-month bundle price on its terms page, which is why the monthly price is quoted here. Its homepage says "No membership or hidden fees". Compounded; not FDA-approved.

    Partner: This seller may pay us a referral fee if you buy through our link, at no extra cost to you. That moves it up in our default order, never in a lowest-cost sort, and is not a medical recommendation.

    Confirm the prescribed dose, supply length, membership or consultation fees, and refill conditions with the seller. A listed offer does not confirm eligibility or stock.

    Advertised price as read on its own page (joinem.co)
  • View
    $149/mo (lttl.com/weight-loss)

    ≈ $159.64 per 30 days

    Checked on lttl.com

    Top dose: same price at 15 mg

    Terms & source

    Advertised price: "Monthly Auto-Refill", "4-Week Supply · Cancel anytime", "$149/mo every month" (its plans page), pay as you go; the 3, 6 and 12-month plans are 12, 24 and 52-week supplies: $146 a month on a 3-month plan ($438 quarterly), $143 on 6 months ($858 every 6 months), $139 on 12 months ($1,668 annually); the same price at every dose, shipping free

    28-day supply (lttl.com)

    ≈ $159.64 per 30 days at this quoted rate

    Other plan lengths

    • $146/28 days on 3 months ($438 up front)
    • $143/28 days on 6 months ($858 up front)
    • $139/28 days on 12 months ($1,668 up front)

    Top-dose terms: The seller states one price at every dose, so this is also its price at 15 mg.

    Lttl says "Same price at every dose" and "One flat price for every dose"; it advertises "Up to $140 off your first month" with a code applied automatically and no end date. Cancel by emailing its care team; orders already processed by the pharmacy cannot be canceled or refunded. Plans sold in U.S. states where its partner providers are licensed. Compounded products are not FDA-approved.

    Partner: This seller may pay us a referral fee if you buy through our link, at no extra cost to you. That moves it up in our default order, never in a lowest-cost sort, and is not a medical recommendation.

    Confirm the prescribed dose, supply length, membership or consultation fees, and refill conditions with the seller. A listed offer does not confirm eligibility or stock.

    Advertised price as read on its own page (lttl.com)
  • View
    $128/mo (biotechlifestyle.com/pricing)

    Checked on biotechlifestyle.com

    Top dose:$184/mo (biotechlifestyle.com/pricing)at 15 mg

    Checked on biotechlifestyle.com

    Terms & source

    Advertised price: monthly plan "$128 to $184 per month, by dose", "$128 at 2.5 mg, $140 at 5 mg, $146 at 7.5 mg, $159 at 10 mg, $171 at 12.5 mg, $184 at 15 mg per month"; 90-day plan "$330 per 90 days, $110/month, every dose"; "The monthly plan is billed one month at a time"; "You can adjust or cancel anytime."; "On the monthly plan the price follows your weekly dose, so a higher dose costs more"

    Billed per month; days of supply not on record, so ordered as four weekly doses.

    Other plan lengths

    • $110/mo on 3 months ($330 up front)

    New patients: "Compounded tirzepatide with vitamin B12 is $99 for your first month", applied automatically with no code, then the dose price. "There is no membership fee"; the price includes the provider visit, injection supplies and free overnight shipping. A comparison site lists it at $184 a month, which is its top-dose price; its shop page shows "From $110.00" a month, which is the 90-day plan. Compounded; not FDA-approved.

    Partner: This seller may pay us a referral fee if you buy through our link, at no extra cost to you. That moves it up in our default order, never in a lowest-cost sort, and is not a medical recommendation.

    Confirm the prescribed dose, supply length, membership or consultation fees, and refill conditions with the seller. A listed offer does not confirm eligibility or stock.

    Advertised price as read on its own page (biotechlifestyle.com)

Read prices in context. Compare the same product, dose and payment terms; missing prices are not estimated. Compounded medicines are not FDA-approved.

How this list is ordered. Lowest price first, with partners moved up: sellers that may pay us a referral fee, as each one's terms say. A partner is moved up, not put first: a much cheaper seller still comes before it. This never changes what you pay; sort by lowest cost to see price order alone.

How prices are compared, what FDA says about compounding and how we earn

A prepaid monthly rate is not a monthly payment. Cost order uses current, recently checked quotes, converted to 30 days: by the supply a price buys where the seller states it in days, otherwise a monthly price with its plan length on record read as four weekly doses, a yearly membership in the price spread over twelve months. Introductory prices, ranges, prices with no plan length on record and separately billed fees are unranked references. Dose changes and added fees affect what you pay.

A listed maintenance dose is not a dosing recommendation.

FDA declared the tirzepatide (December 2024) and semaglutide (February 2025) shortages resolved (fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize). Its conditions for a pharmacy compounding them now include "The drug product is compounded for an individual patient based on receipt of a prescription" and "The compounder does not compound, regularly or in inordinate amounts, any that are essentially copies of a commercially available drug product." (fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize) In May 2026 FDA proposed leaving semaglutide, tirzepatide and liraglutide off the 503B Bulks List (federalregister.gov/documents/2026/05/01/2026-08552/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal), the ingredients outsourcing facilities may compound from; comments closed Jul 30, 2026 (govinfo.gov/content/pkg/FR-2026-06-26/html/2026-12937.htm), and we found no final notice when we last read the Federal Register (Nov 6, 2026). FDA's newest warning letter to a pharmacy over compounded semaglutide or tirzepatide went to Empower Clinic Services, LLC dba Empower Pharmacy (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/empower-clinic-services-llc-dba-empower-pharmacy-738238-09182026) on Sep 18, 2026 (every GLP-1 warning letter). FDA's newest recall report of a compounded semaglutide or tirzepatide product is Houston Rx LLC's tirzepatide (api.fda.gov/drug/enforcement.json), reported Oct 21, 2026: "Lack of assurance of sterility." (every tirzepatide recall). Liraglutide is different: FDA's shortage database (accessdata.fda.gov/scripts/drugshortages) still lists it in shortage (updated at source Oct 14, 2026; every GLP-1 shortage). FDA: "Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed." (fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers) A low price is not a low-risk signal; confirm current terms with the provider.

GLPcompare links out only to sellers with a referral program: if you sign up or buy through one of those links, we may earn a commission at no extra cost to you. For other sellers we show the price and the seller's address, and suggest sellers we can link to. It never changes the price you pay or the underlying data. Our default order is lowest price first, with sellers that pay us moved up, and the note under each list says which order it shows; every lowest-cost sort uses the price alone. In a price table, a partner's offer says so in its terms. The order is not a medical recommendation; a higher-placed offer is not necessarily the lowest price or the right product for you.

Prices are self-pay cash figures a person pays, not pharmacy acquisition costs. They change often; each names its source. Every cash quote was checked on or after Nov 6, 2026. Compounded semaglutide and tirzepatide are prepared by pharmacies and are not FDA-approved. This is information, not medical advice.

Indications

Brands, formulations & approved uses

Mounjaro

  • InjectionOnce weekly

    Glucose control in adults and children 10+ with type 2 diabetes; cardiovascular risk reduction in adults with type 2 diabetes at high cardiovascular risk.

    Prescribing information (pi.lilly.com) · Reviewed Nov 4, 2026

Zepbound

  • InjectionOnce weekly

    Weight management in adults with obesity, or overweight with a weight-related condition; moderate to severe obstructive sleep apnea in adults with obesity.

    Prescribing information (pi.lilly.com) · Reviewed Nov 4, 2026

A single molecule that activates both the GIP and GLP-1 receptors, combining incretin pathways to improve glycemic control and reduce body weight.

Availability

Shortage status

No shortage reported

No matching shortage record was returned in the latest complete FDA check. Check the FDA database (accessdata.fda.gov).

Last complete check: Nov 17, 2026

Pricing

Pharmacy acquisition-cost reference

NADAC measures pharmacy acquisition costs per unit, not what you pay. Different strengths and concentrations are not equivalent monthly supplies.

View pharmacy and policy price references
  • Mounjaro 10 MG/0.5 ML Pen
    NDC 00002147180
    Acquisition
    $538.75779/mL (data.medicaid.gov/api/1/datastore/query/5145182d-8c6e-5464-a999-819ce26b0e2d)
    Effective Oct 21, 2026
    CMS release Nov 11, 2026
    Checked Nov 16, 2026
  • Mounjaro 12.5 MG/0.5 ML Pen
    NDC 00002146080
    Acquisition
    $538.58594/mL (data.medicaid.gov/api/1/datastore/query/5145182d-8c6e-5464-a999-819ce26b0e2d)
    Effective Oct 21, 2026
    CMS release Nov 11, 2026
    Checked Nov 16, 2026
  • Mounjaro 15 MG/0.5 ML Pen
    NDC 00002145780
    Acquisition
    $538.5675/mL (data.medicaid.gov/api/1/datastore/query/5145182d-8c6e-5464-a999-819ce26b0e2d)
    Effective Oct 21, 2026
    CMS release Nov 11, 2026
    Checked Nov 16, 2026
  • Mounjaro 2.5 MG/0.5 ML Pen
    NDC 00002150680
    Acquisition
    $538.75037/mL (data.medicaid.gov/api/1/datastore/query/5145182d-8c6e-5464-a999-819ce26b0e2d)
    Effective Oct 21, 2026
    CMS release Nov 11, 2026
    Checked Nov 16, 2026
  • Mounjaro 5 MG/0.5 ML Pen
    NDC 00002149580
    Acquisition
    $538.69656/mL (data.medicaid.gov/api/1/datastore/query/5145182d-8c6e-5464-a999-819ce26b0e2d)
    Effective Oct 21, 2026
    CMS release Nov 11, 2026
    Checked Nov 16, 2026
  • Mounjaro 7.5 MG/0.5 ML Pen
    NDC 00002148480
    Acquisition
    $538.74363/mL (data.medicaid.gov/api/1/datastore/query/5145182d-8c6e-5464-a999-819ce26b0e2d)
    Effective Oct 21, 2026
    CMS release Nov 11, 2026
    Checked Nov 16, 2026
  • Zepbound 10 MG/0.5 ML Pen
    NDC 00002247180
    Acquisition
    $526.06981/mL (data.medicaid.gov/api/1/datastore/query/5145182d-8c6e-5464-a999-819ce26b0e2d)
    Effective Oct 21, 2026
    CMS release Nov 11, 2026
    Checked Nov 16, 2026
  • Zepbound 10 Mg/dose (40 MG/2.4 Ml) Kwikpen
    NDC 00002353301
    Acquisition
    $281.78403/mL (data.medicaid.gov/api/1/datastore/query/5145182d-8c6e-5464-a999-819ce26b0e2d)
    Effective Oct 21, 2026
    CMS release Nov 11, 2026
    Checked Nov 16, 2026
  • Zepbound 10 Mg/dose (40 MG/2.4 Ml) Kwikpen
    NDC 00002353311
    Acquisition
    $281.78403/mL (data.medicaid.gov/api/1/datastore/query/5145182d-8c6e-5464-a999-819ce26b0e2d)
    Effective Oct 21, 2026
    CMS release Nov 11, 2026
    Checked Nov 16, 2026
  • Zepbound 12.5 MG/0.5 ML Pen
    NDC 00002246080
    Acquisition
    $525.83386/mL (data.medicaid.gov/api/1/datastore/query/5145182d-8c6e-5464-a999-819ce26b0e2d)
    Effective Oct 21, 2026
    CMS release Nov 11, 2026
    Checked Nov 16, 2026
  • Zepbound 12.5 Mg/dose (50 MG/2.4 Ml) Kwikpen
    NDC 00002352201
    Acquisition
    $282.2326/mL (data.medicaid.gov/api/1/datastore/query/5145182d-8c6e-5464-a999-819ce26b0e2d)
    Effective Oct 21, 2026
    CMS release Nov 11, 2026
    Checked Nov 16, 2026
  • Zepbound 12.5 Mg/dose (50 MG/2.4 Ml) Kwikpen
    NDC 00002352211
    Acquisition
    $282.2326/mL (data.medicaid.gov/api/1/datastore/query/5145182d-8c6e-5464-a999-819ce26b0e2d)
    Effective Oct 21, 2026
    CMS release Nov 11, 2026
    Checked Nov 16, 2026
  • Zepbound 15 MG/0.5 ML Pen
    NDC 00002245780
    Acquisition
    $525.93123/mL (data.medicaid.gov/api/1/datastore/query/5145182d-8c6e-5464-a999-819ce26b0e2d)
    Effective Oct 21, 2026
    CMS release Nov 11, 2026
    Checked Nov 16, 2026
  • Zepbound 15 Mg/dose (60 MG/2.4 Ml) Kwikpen
    NDC 00002351101
    Acquisition
    $281.67525/mL (data.medicaid.gov/api/1/datastore/query/5145182d-8c6e-5464-a999-819ce26b0e2d)
    Effective Oct 21, 2026
    CMS release Nov 11, 2026
    Checked Nov 16, 2026
  • Zepbound 15 Mg/dose (60 MG/2.4 Ml) Kwikpen
    NDC 00002351111
    Acquisition
    $281.67525/mL (data.medicaid.gov/api/1/datastore/query/5145182d-8c6e-5464-a999-819ce26b0e2d)
    Effective Oct 21, 2026
    CMS release Nov 11, 2026
    Checked Nov 16, 2026
  • Zepbound 2.5 MG/0.5 ML Pen
    NDC 00002250680
    Acquisition
    $526.2285/mL (data.medicaid.gov/api/1/datastore/query/5145182d-8c6e-5464-a999-819ce26b0e2d)
    Effective Oct 21, 2026
    CMS release Nov 11, 2026
    Checked Nov 16, 2026
  • Zepbound 2.5 Mg/dose (10 MG/2.4 Ml) Kwikpen
    NDC 00002356601
    Acquisition
    $201.38737/mL (data.medicaid.gov/api/1/datastore/query/5145182d-8c6e-5464-a999-819ce26b0e2d)
    Effective Oct 21, 2026
    CMS release Nov 11, 2026
    Checked Nov 16, 2026
  • Zepbound 2.5 Mg/dose (10 MG/2.4 Ml) Kwikpen
    NDC 00002356611
    Acquisition
    $201.38737/mL (data.medicaid.gov/api/1/datastore/query/5145182d-8c6e-5464-a999-819ce26b0e2d)
    Effective Oct 21, 2026
    CMS release Nov 11, 2026
    Checked Nov 16, 2026
  • Zepbound 5 MG/0.5 ML Pen
    NDC 00002249580
    Acquisition
    $526.09535/mL (data.medicaid.gov/api/1/datastore/query/5145182d-8c6e-5464-a999-819ce26b0e2d)
    Effective Oct 21, 2026
    CMS release Nov 11, 2026
    Checked Nov 16, 2026
  • Zepbound 5 Mg/dose (20 MG/2.4 Ml) Kwikpen
    NDC 00002355501
    Acquisition
    $201.19861/mL (data.medicaid.gov/api/1/datastore/query/5145182d-8c6e-5464-a999-819ce26b0e2d)
    Effective Oct 21, 2026
    CMS release Nov 11, 2026
    Checked Nov 16, 2026
  • Zepbound 5 Mg/dose (20 MG/2.4 Ml) Kwikpen
    NDC 00002355511
    Acquisition
    $201.19861/mL (data.medicaid.gov/api/1/datastore/query/5145182d-8c6e-5464-a999-819ce26b0e2d)
    Effective Oct 21, 2026
    CMS release Nov 11, 2026
    Checked Nov 16, 2026
  • Zepbound 7.5 MG/0.5 ML Pen
    NDC 00002248480
    Acquisition
    $526.04136/mL (data.medicaid.gov/api/1/datastore/query/5145182d-8c6e-5464-a999-819ce26b0e2d)
    Effective Oct 21, 2026
    CMS release Nov 11, 2026
    Checked Nov 16, 2026
  • Zepbound 7.5 Mg/dose (30 MG/2.4 Ml) Kwikpen
    NDC 00002354401
    Acquisition
    $201.16042/mL (data.medicaid.gov/api/1/datastore/query/5145182d-8c6e-5464-a999-819ce26b0e2d)
    Effective Oct 21, 2026
    CMS release Nov 11, 2026
    Checked Nov 16, 2026
  • Zepbound 7.5 Mg/dose (30 MG/2.4 Ml) Kwikpen
    NDC 00002354411
    Acquisition
    $201.16042/mL (data.medicaid.gov/api/1/datastore/query/5145182d-8c6e-5464-a999-819ce26b0e2d)
    Effective Oct 21, 2026
    CMS release Nov 11, 2026
    Checked Nov 16, 2026
  • Mounjaro, Federal Direct
    Cash
    $499.00/month (trumprx.gov/p/mounjaro)
    Checked Nov 17, 2026
  • Zepbound, Federal Direct
    Cash
    $299.00/month (trumprx.gov/p/zepbound)
    Checked Nov 17, 2026

Source: NADAC (Data.Medicaid.gov) (data.medicaid.gov/api/1/datastore/query/5145182d-8c6e-5464-a999-819ce26b0e2d) · as of Nov 16, 2026

The ingredient index tracks pharmacy acquisition costs over windows up to 53 days long, not patient cash prices or just the presentation listed above. Each NDC starts at 100; we average its percentage change with the same NDCs at every point, so per-tablet and per-mL dollar prices are never averaged together. Incomplete days are omitted. “Flat” means a change smaller than 0.5%. Insufficient or truncated history shows no index.

NADAC is the average price pharmacies pay to acquire a drug, not the cash price at the counter. Compounded and cash prices, where shown, are labeled and are not FDA-approved list prices.

Patient copay

Medicare GLP-1 Bridge

For eligible Part D enrollees using a covered product for weight management, with prior authorization. Bridge operates outside the Part D benefit. Its copay does not count toward Part D out-of-pocket spending, and the Part D deductible does not apply.

Published effective dates: to

Check Medicare eligibility and coverage (medicare.gov)Who qualifies and how to get it
  • Zepbound

    KwikPen only. Single-dose pens and vials are excluded.

    $50 (cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge) (Patient copay for Zepbound; per 28- or 30-day fill)

    per 28- or 30-day fill

CMS program details (cms.gov)Covered products (CMS PDF) (cms.gov)Source reviewed
From FDA and CMS records

Tirzepatide: timing, generics and coverage

Read from each FDA label, FDA's Orange Book and CMS's Part D files, and updated when they change.

BrandSoonest top doseHalf-lifeGeneric approved?Patent on the medicine toOn Medicare Part D, 2025
Mounjaro15 mg from week 21about 5 daysNoJun 14, 20391,592,517
Zepbound15 mg from week 21about 5-6 daysNoMay 13, 2036160,298

How long each takes · Generics and patents · Who covers what

Product labeling

Dosing, warnings & contraindications

Choose the named product and route. These are submitted label records, which may differ from current approved prescribing information. The product links above lead to current prescribing information. Indexed text omits tables and images; always read the full source label.

Showing the most recently effective indexed record for each brand and route combination. Alternate submissions and older records are linked below.

Mounjaro / Mounjaro KwikPen

SUBCUTANEOUS · Eli Lilly and Company

Label effective · version 40Retrieved · Nov 17, 2026 UTCFull label on DailyMed (dailymed.nlm.nih.gov)Indexed source record (api.fda.gov)
Read indexed warnings and label text

Boxed warning

WARNING: RISK OF THYROID C-CELL TUMORS In both male and female rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined [see Warnings and Precautions ( 5.1 ) and Nonclinical Toxicology ( 13.1 )]. MOUNJARO is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Contraindications ( 4 )] . Counsel patients regarding the potential risk for MTC with the use of MOUNJARO and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with MOUNJARO [see Contraindications ( 4 ) and Warnings and Precautions ( 5.1 )]. WARNING: RISK OF THYROID C-CELL TUMORS See full prescribing information for complete boxed warning. Tirzepatide causes thyroid C-cell tumors in rats. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined ( 5.1 , 13.1 ). MOUNJARO is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and symptoms of thyroid tumors ( 4 , 5.1 ).

Contraindications

4 CONTRAINDICATIONS MOUNJARO is contraindicated in patients with: A personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Warnings and Precautions ( 5.1 )] . Known serious hypersensitivity to tirzepatide or any of the excipients in MOUNJARO. Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with MOUNJARO [see Warnings and Precautions ( 5.4 )] . Personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2. ( 4 ) Known serious hypersensitivity to tirzepatide or any of the excipients in MOUNJARO. ( 4 )

Indications and uses

1 INDICATIONS AND USAGE MOUNJARO ® is indicated: as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction (MI), or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events. MOUNJARO ® is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated: as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. ( 1 ) to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events. ( 1 )

Dosing and administration

2 DOSAGE AND ADMINISTRATION The recommended starting dosage is 2.5 mg injected subcutaneously once weekly. ( 2.1 ) If additional glycemic control is needed, increase the dosage in 2.5 mg increments after at least 4 weeks on the current dose. ( 2.1 ) Maximum dosage ( 2.1 ): Adults: 15 mg subcutaneously once weekly. Pediatric patients 10 years of age and older: 10 mg subcutaneously once weekly. Administer once weekly at any time of day, with or without meals. ( 2.2 ) Inject subcutaneously in the abdomen, thigh, or have another person inject in the back of the upper arm. Rotate injection sites with each dose. ( 2.2 ) Refer to the Full Prescribing Information for additional important administration instructions about MOUNJARO presentations. ( 2.2 ) 2.1 Recommended Dosage Follow the starting dosage recommendation and dosage escalation schedule below to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions ( 5.6 ) and Adverse Reactions ( 6.1 )]. Recommended Starting Dosage and Escalation The recommended starting dosage of MOUNJARO is 2.5 mg injected subcutaneously once weekly [see Dosage and Administration ( 2.2 )] . If additional glycemic control is needed, increase the dosage in 2.5 mg increments after at least 4 weeks on the current dose. The maximum dosage of MOUNJARO is: 15 mg injected subcutaneously once weekly in adults. 10 mg injected subcutaneously once weekly in pediatric patients. Recommendations Regarding Missed Doses If a dose is missed, instruct patients to administer MOUNJARO as soon as possible within 4 days (96 hours) after the missed dose. If more than 4 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day. In each case, patients can then resume their regular once weekly dosing schedule. The day of weekly administration can be changed, if necessary, as long as the time between the two doses is at least 3 days (72 hours). 2.2 Important Administration Instructions Inform patients and their caregiver(s) which MOUNJARO presentation (e.g., vial, pre-filled single-dose pen, single-patient-use KwikPen) they will receive and ensure they receive training appropriate for that specific presentation. If the prescribed MOUNJARO presentation changes, ensure patients and caregivers receive appropriate training and instruct them to consult the Instructions for Use for the newly prescribed presentation. Prior to initiation, train patients and their caregiver(s) on proper injection technique for the prescribed MOUNJARO presentation [see Instructions for Use] . After training, a patient may self-inject MOUNJARO if the healthcare provider determines that it can be properly administered, except for the following: MOUNJARO KwikPen is not recommended for self-administration by pediatric patients. MOUNJARO KwikPen is not recommended for self-administration by those who are visually impaired. Instruct patients using MOUNJARO vials to use a syringe appropriate for dose administration (e.g., a 1 mL syringe capable of measuring a 0.5 mL or 0.6 mL dose) and always use a new syringe and needle for each injection. Administer MOUNJARO once weekly, any time of day, with or without meals. Inject MOUNJARO subcutaneously in the abdomen, thigh, or have another person inject MOUNJARO in the back of the upper arm. Rotate injection sites with each dose. Inspect MOUNJARO visually before use. It should appear clear and colorless to slightly yellow. Do not use MOUNJARO if particulate matter or discoloration is seen. When using MOUNJARO with insulin, administer as separate injections and never mix. It is acceptable to inject MOUNJARO and insulin in the same body region, but the injections should not be adjacent to each other.

Warnings and precautions

5 WARNINGS AND PRECAUTIONS Acute Pancreatitis: Has been observed in patients treated with GLP-1 receptor agonists, or MOUNJARO. Discontinue if pancreatitis is suspected. ( 5.2 ) Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin: Concomitant use with an insulin secretagogue or insulin may increase the risk of hypoglycemia, including severe hypoglycemia. Reducing dose of insulin secretagogue or insulin may be necessary. ( 5.3 ) Hypersensitivity Reactions: Serious hypersensitivity reactions (e.g., anaphylaxis and angioedema) have been reported. Discontinue MOUNJARO if suspected and promptly seek medical advice. ( 5.4 ) Acute Kidney Injury Due to Volume Depletion: Monitor renal function in patients reporting adverse reactions that could lead to volume depletion. ( 5.5 ) Severe Gastrointestinal Adverse Reactions: Use has been associated with gastrointestinal adverse reactions, sometimes severe. MOUNJARO is not recommended in patients with severe gastroparesis. ( 5.6 ) Diabetic Retinopathy Complications in Patients with a History of Diabetic Retinopathy: Monitor patients with a history of diabetic retinopathy for progression. ( 5.7 ) Acute Gallbladder Disease: Has occurred in clinical trials. If cholelithiasis is suspected, gallbladder studies and clinical follow-up are indicated. ( 5.8 ) Pulmonary Aspiration During General Anesthesia or Deep Sedation: Has been reported in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures. Instruct patients to inform healthcare providers of any planned surgeries or procedures. ( 5.9 ) Never Share a MOUNJARO KwikPen Between Patients: even if the pen needle is changed. ( 5.10 ) 5.1 Risk of Thyroid C-Cell Tumors In both sexes of rats, tirzepatide caused a dose-dependent and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) in a 2-year study at clinically relevant plasma exposures [see Nonclinical Toxicology ( 13.1 )] . It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined. MOUNJARO is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2. Counsel patients regarding the potential risk for MTC with the use of MOUNJARO and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with MOUNJARO. Such monitoring may increase the risk of unnecessary procedures, due to the low test specificity for serum calcitonin and a high background incidence of thyroid disease. Significantly elevated serum calcitonin values may indicate MTC and patients with MTC usually have calcitonin values >50 ng/L. If serum calcitonin is measured and found to be elevated, the patient should be further evaluated. Patients with thyroid nodules noted on physical examination or neck imaging should also be further evaluated. 5.2 Acute Pancreatitis Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, or MOUNJARO [see Adverse Reactions ( 6 )] . After initiation of MOUNJARO, observe patients carefully for signs and symptoms of acute pancreatitis, which may include persistent or severe abdominal pain (sometimes radiating to the back) and which may or may not be accompanied by nausea or vomiting. If pancreatitis is suspected, discontinue MOUNJARO and initiate appropriate management. 5.3 Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin Patients receiving MOUNJARO in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia [see Adverse Reactions ( 6.1 ), Drug Interactions ( 7.1 )] . The risk of hypoglycemia may be lowered by a reduction in the dose of sulfonylurea (or other concomitantly administered insulin secretagogue) or insulin. Inform patients using these concomitant medications of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia. 5.4 Hypersensitivity Reactions Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported in patients treated with MOUNJARO. If hypersensitivity reactions occur, discontinue use of MOUNJARO; treat promptly per standard of care, and monitor until signs and symptoms resolve. Do not use in patients with a previous serious hypersensitivity reaction to tirzepatide or any of the excipients in MOUNJARO [see Contraindications ( 4 ), Adverse Reactions ( 6.2 )] . Anaphylaxis and angioedema have been reported with GLP-1 receptor agonists. Use caution in patients with a history of angioedema or anaphylaxis with a GLP-1 receptor agonist because it is unknown whether such patients will be predisposed to these reactions with MOUNJARO. 5.5 Acute Kidney Injury Due to Volume Depletion There have been postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with GLP-1 receptor agonists, or MOUNJARO. The majority of the reported events occurred in patients who experienced gastrointestinal adverse reactions leading to dehydration such as nausea, vomiting, or diarrhea [see Adverse Reactions ( 6 )] . Monitor renal function in patients reporting adverse reactions to MOUNJARO that could lead to volume depletion, especially during dosage initiation and escalation of MOUNJARO. 5.6 Severe Gastrointestinal Adverse Reactions Use of MOUNJARO has been associated with gastrointestinal adverse reactions, sometimes severe [see Adverse Reactions ( 6 )] . In the pool of placebo-controlled trials in adults, severe gastrointestinal adverse reactions occurred more frequently among patients receiving MOUNJARO (5 mg 1.3%, 10 mg 0.4%, 15 mg 1.2%) than placebo (0.9%). Severe gastrointestinal adverse reactions have also been reported postmarketing with GLP-1 receptor agonists. MOUNJARO is not recommended in patients with severe gastroparesis. 5.7 Diabetic Retinopathy Complications in Patients with a History of Diabetic Retinopathy Temporary worsening of diabetic retinopathy has been reported with rapid improvement in glucose control. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy. 5.8 Acute Gallbladder Disease Acute events of gallbladder disease such as cholelithiasis or cholecystitis have been reported in GLP-1 receptor agonist trials and postmarketing. In MOUNJARO placebo-controlled clinical trials in adults, acute gallbladder disease (cholelithiasis, biliary colic, and cholecystectomy) was reported by 0.6% of MOUNJARO-treated patients and 0% of placebo-treated patients. If cholelithiasis is suspected, gallbladder diagnostic studies and appropriate clinical follow-up are indicated. 5.9 Pulmonary Aspiration During General Anesthesia or Deep Sedation MOUNJARO delays gastric emptying [see Clinical Pharmacology ( 12.2 )] . There have been rare postmarketing reports of pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations. Available data are insufficient to inform recommendations to mitigate the risk of pulmonary aspiration during general anesthesia or deep sedation in patients taking MOUNJARO, including whether modifying preoperative fasting recommendations or temporarily discontinuing MOUNJARO could reduce the incidence of retained gastric contents. Instruct patients to inform healthcare providers prior to any planned surgeries or procedures if they are taking MOUNJARO. 5.10 Never Share a MOUNJARO KwikPen Between Patients Never share MOUNJARO KwikPen between patients, even if the pen needle is changed. Sharing poses a risk for transmission of blood-borne pathogens.

Drug interactions

7 DRUG INTERACTIONS MOUNJARO delays gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications. ( 7.2 ) 7.1 Concomitant Use with an Insulin Secretagogue (e.g., Sulfonylurea) or with Insulin When initiating MOUNJARO, consider reducing the dose of concomitantly administered insulin secretagogues (e.g., sulfonylureas) or insulin to reduce the risk of hypoglycemia [see Warnings and Precautions ( 5.3 )]. 7.2 Oral Medications MOUNJARO delays gastric emptying and thereby has the potential to impact the absorption of concomitantly administered oral medications. Caution should be exercised when oral medications are concomitantly administered with MOUNJARO. Monitor patients on oral medications dependent on threshold concentrations for efficacy and those with a narrow therapeutic index (e.g., warfarin) when concomitantly administered with MOUNJARO. Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation with MOUNJARO. Hormonal contraceptives that are not administered orally should not be affected [see Use in Specific Populations ( 8.3 ) and Clinical Pharmacology ( 12.2 , 12.3 )].

Adverse reactions

6 ADVERSE REACTIONS The following serious adverse reactions are described below or elsewhere in the prescribing information: Risk of Thyroid C-cell Tumors [see Warnings and Precautions ( 5.1 )] Acute Pancreatitis [see Warnings and Precautions ( 5.2 )] Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions ( 5.3 )] Hypersensitivity Reactions [see Warnings and Precautions ( 5.4 )] Acute Kidney Injury Due to Volume Depletion [see Warnings and Precautions ( 5.5 )] Severe Gastrointestinal Adverse Reactions [see Warnings and Precautions ( 5.6 )] Diabetic Retinopathy Complications in Patients with a History of Diabetic Retinopathy [see Warnings and Precautions ( 5.7 )] Acute Gallbladder Disease [see Warnings and Precautions ( 5.8 )] Pulmonary Aspiration During General Anesthesia or Deep Sedation [see Warnings and Precautions ( 5.9 )] The most common adverse reactions, reported in ≥5% of patients treated with MOUNJARO are nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Adverse Reactions in the Clinical Trials of Adults with Type 2 Diabetes Mellitus Pool of Two Placebo-Controlled Clinical Trials in Adults The data in Table 1 are derived from 2 placebo-controlled trials [1 monotherapy trial (SURPASS-1) and 1 trial in combination with basal insulin with or without metformin (SURPASS-5)] in adult patients with type 2 diabetes mellitus [see Clinical Studies ( 14.2 , 14.4 )] . These data reflect exposure of 718 patients to MOUNJARO and a mean duration of exposure to MOUNJARO of 36.6 weeks. The mean age of patients was 58 years, 4% were 75 years or older and 54% were male. The population was 57% White, 27% Asian, 13% American Indian or Alaska Native, and 3% Black or African American; 25% identified as Hispanic or Latino ethnicity. At baseline, patients had type 2 diabetes mellitus for an average of 9.1 years with a mean HbA1c of 8.1%. As assessed by baseline fundoscopic examination, 13% of the population had retinopathy. At baseline, eGFR was ≥90 mL/min/1.73 m 2 in 53%, 60 to 90 mL/min/1.73 m 2 in 39%, 45 to 60 mL/min/1.73 m 2 in 7%, and 30 to 45 mL/min/1.73 m 2 in 1% of patients. Pool of Seven Controlled Clinical Trials Adverse reactions were also evaluated in a larger pool of adult patients with type 2 diabetes mellitus participating in seven controlled clinical trials which included two placebo-controlled trials (SURPASS-1 and -5), three trials of MOUNJARO in combination with metformin, sulfonylureas, and/or SGLT2 Inhibitors (SURPASS-2, -3, -4) [see Clinical Studies ( 14.3 )] and two additional trials conducted in Japan. In this pool, a total of 5119 adult patients with type 2 diabetes mellitus were treated with MOUNJARO for a mean duration of 48.1 weeks. The mean age of patients was 58 years, 4% were 75 years or older and 58% were male. The population was 65% White, 24% Asian, 7% American Indian or Alaska Native, and 3% Black or African American; 38% identified as Hispanic or Latino ethnicity. At baseline, patients had type 2 diabetes mellitus for an average of 9.1 years with a mean HbA1c of 8.3%. As assessed by baseline fundoscopic examination, 15% of the population had retinopathy. At baseline, eGFR was ≥90 mL/min/1.73 m 2 in 52%, 60 to 90 mL/min/1.73 m 2 in 40%, 45 to 60 mL/min/1.73 m 2 in 6%, and 30 to 45 mL/min/1.73 m 2 in 1% of patients. Common Adverse Reactions in Adults Table 1 shows common adverse reactions, not including hypoglycemia, associated with the use of MOUNJARO in the pool of placebo-controlled trials in adults. These adverse reactions occurred more commonly on MOUNJARO than on placebo and occurred in at least 5% of patients treated with MOUNJARO. Table 1: Adverse Reactions in Pool of Placebo-Controlled Trials Reported in ≥5% of MOUNJARO-treated Adult Patients with Type 2 Diabetes Mellitus Note: Percentages reflect the number of patients who reported at least 1 occurrence of the adverse reaction. Adverse Reaction Placebo (N=235) % MOUNJARO 5 mg (N=237) % MOUNJARO 10 mg (N=240) % MOUNJARO 15 mg (N=241) % Nausea 4 12 15 18 Diarrhea 9 12 13 17 Decreased Appetite 1 5 10 11 Vomiting 2 5 5 9 Constipation 1 6 6 7 Dyspepsia 3 8 8 5 Abdominal Pain 4 6 5 5 In the pool of seven clinical trials in adults, the types and frequency of common adverse reactions, not including hypoglycemia, were similar to those listed in Table 1 . In a CV outcomes trial of 6,647 adults with type 2 diabetes mellitus and established CV disease exposed to MOUNJARO, adverse reactions reported with MOUNJARO were similar with the exception of dysesthesia (0.7%), decreased appetite (17%), constipation (13%), vomiting (12%), abdominal pain (10%), and fatigue (10%) [see Clinical Studies ( 14.6 )] . Gastrointestinal Adverse Reactions In the pool of placebo-controlled trials in adults, gastrointestinal adverse reactions occurred more frequently among patients receiving MOUNJARO than placebo (placebo 20.4%, MOUNJARO 5 mg 37.1%, MOUNJARO 10 mg 39.6%, MOUNJARO 15 mg 43.6%). More patients receiving MOUNJARO 5 mg (3.0%), MOUNJARO 10 mg (5.4%), and MOUNJARO 15 mg (6.6%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation and decreased over time. The following gastrointestinal adverse reactions were reported more frequently in MOUNJARO-treated adult patients than placebo-treated patients (frequencies listed, respectively, as: placebo; 5 mg; 10 mg; 15 mg): eructation (0.4%, 3.0%, 2.5%, 3.3%), flatulence (0%, 1.3%, 2.5%, 2.9%), gastroesophageal reflux disease (0.4%, 1.7%, 2.5%, 1.7%), abdominal distension (0.4%, 0.4%, 2.9%, 0.8%). Adverse Reactions in the Clinical Trial of Pediatric Patients 10 Years of Age and Older with Type 2 Diabetes Mellitus MOUNJARO was administered to 97 pediatric patients 10 years of age and older with type 2 diabetes mellitus for a mean duration of 39.9 weeks [see Clinical Studies ( 14.5 )] . The mean age was 15 years and 61% of patients were female. The population was 58% White, 11% Black or African American, 6% Asian, 20% American Indian or Alaska Native, and 5% were other races; 66% identified as Hispanic or Latino ethnicity. At baseline, pediatric patients had type 2 diabetes mellitus for an average of 2.4 years with a mean HbA1c of 8.0%. The incidences of adverse reactions reported in pediatric patients treated with MOUNJARO 5 mg and 10 mg subcutaneously once-weekly were consistent with those described above for adult patients with type 2 diabetes mellitus with the exception of a higher incidence of vomiting, abdominal pain, and hypoglycemia. During the 30-week placebo-controlled period of the study, vomiting occurred in 3%, 16%, and 12% of patients and abdominal pain occurred in 9%, 22%, and 15% of patients treated with placebo, MOUNJARO 5 mg, and 10 mg, respectively. Other Adverse Reactions in Adults and Pediatric Patients 10 Years of Age and Older with Type 2 Diabetes Mellitus Hypoglycemia Adults with Type 2 Diabetes Mellitus Table 2 summarizes the incidence of hypoglycemic events in the placebo-controlled trials in adults. Table 2: Hypoglycemia Adverse Reactions in Placebo-Controlled Trials in Adult Patients with Type 2 Diabetes Mellitus Note: Percentages reflect the number of patients who reported at least 1 episode of hypoglycemia in respective categories. * Reflects the study treatment period. Data include events occurring during 4 weeks of treatment-free safety follow up. Events after introduction of a new glucose-lowering treatment are excluded. ** Episodes requiring the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Placebo % MOUNJARO 5 mg % MOUNJARO 10 mg % MOUNJARO 15 mg % Monotherapy (40 weeks)* N=115 N=121 N=119 N=120 Blood glucose <54 mg/dL 1 0 0 0 Severe hypoglycemia** 0 0 0 0 Add-on to Basal Insulin with or without Metformin (40 weeks)* N=120 N=116 N=119 N=120 Blood glucose <54 mg/dL 13 16 19 14 Severe hypoglycemia** 0 0 2 1 Hypoglycemia was more frequent when MOUNJARO was used in combination with a sulfonylurea [see Clinical Studies ( 14 )] . In an adult clinical trial up to 104 weeks of treatment, when administered with a sulfonylurea, hypoglycemia (glucose level <54 mg/dL) occurred in 13.8%, 9.9%, and 12.8%, and severe hypoglycemia occurred in 0.5%, 0%, and 0.6% of patients treated with MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. Pediatric Patients 10 years of Age and Older with Type 2 Diabetes Mellitus No severe hypoglycemia episodes were reported during the trial in pediatric patients 10 years of age and older with type 2 diabetes mellitus. Table 3 summarizes the incidence of hypoglycemic events with blood glucose <54 mg/dL in this trial. Table 3: Hypoglycemia Adverse Reactions in the 30 Week Trial of MOUNJARO Added to Metformin or Basal Insulin, or Both in Pediatric Patients 10 Years of Age and Older with Type 2 Diabetes Mellitus Note: Percentages reflect the number of patients who reported at least 1 episode of blood glucose <54 mg/dL. a Events after the introduction of a new glucose-lowering treatment are excluded. Placebo % MOUNJARO 5 mg % MOUNJARO 10 mg % Add on to basal insulin with or without metformin a N=10 N=10 N=11 Blood glucose <54 mg/dL 10 30 27 Add on to metformin alone a N=24 N=22 N=22 Blood glucose <54 mg/dL 4 9 9 Acute Pancreatitis In clinical studies, 14 events of acute pancreatitis were confirmed by adjudication in 13 MOUNJARO-treated adult patients (0.23 patients per 100 years of exposure) versus 3 events in 3 comparator-treated patients (0.11 patients per 100 years of exposure). Heart Rate Increase In the pool of placebo-controlled trials in adults, treatment with MOUNJARO resulted in a mean increase in heart rate of 2 to 4 beats per minute compared to a mean increase of 1 beat per minute in placebo-treated patients. Episodes of sinus tachycardia, associated with a concomitant increase from baseline in heart rate of ≥15 beats per minute, also were reported in 4.3%, 4.6%, 5.9% and 10% of subjects treated with placebo, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. For patients enrolled in Japan, these episodes were reported in 7% (3/43), 7.1% (3/42), 9.3% (4/43), and 23% (10/43) of patients treated with placebo, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. The clinical relevance of heart rate increases is uncertain. Hypersensitivity Reactions Hypersensitivity reactions have been reported with MOUNJARO in the pool of placebo-controlled trials in adults, sometimes severe (e.g., urticaria and eczema); hypersensitivity reactions were reported in 3.2% of MOUNJARO-treated patients compared to 1.7% of placebo-treated patients. In the pool of seven clinical trials in adults , hypersensitivity reactions occurred in 106/2,570 (4.1%) of MOUNJARO-treated adult patients with anti-tirzepatide antibodies and in 73/2,455 (3.0%) of MOUNJARO-treated patients who did not develop anti-tirzepatide antibodies. In the clinical trial in pediatric patients 10 years of age and older, hypersensitivity reactions occurred in 2/50 (4%) of MOUNJARO-treated pediatric patients with anti-tirzepatide antibodies and in 0/43 (0%) of MOUNJARO-treated pediatric patients who did not develop anti-tirzepatide antibodies [see Clinical Pharmacology ( 12.6 )]. Injection Site Reactions In the pool of placebo-controlled trials in adults, injection site reactions were reported in 3.2% of MOUNJARO-treated patients compared to 0.4% of placebo-treated patients. In the pool of seven clinical trials, injection site reactions occurred in 119/2,570 (4.6%) of MOUNJARO-treated adult patients with anti-tirzepatide antibodies and in 18/2,455 (0.7%) of MOUNJARO-treated adult patients who did not develop anti-tirzepatide antibodies. In the clinical trial in pediatric patients 10 years of age and older, injection site reactions occurred in 3/50 (6%) of MOUNJARO-treated pediatric patients with anti-tirzepatide antibodies and in 0/43 (0%) of MOUNJARO-treated pediatric patients who did not develop anti-tirzepatide antibodies [see Clinical Pharmacology ( 12.6 )]. Acute Gallbladder Disease In the pool of placebo-controlled clinical trials in adults, acute gallbladder disease (cholelithiasis, biliary colic and cholecystectomy) was reported by 0.6% of MOUNJARO-treated patients and 0% of placebo-treated patients. Dysesthesia In the pool of placebo-controlled clinical trials in adults, dysesthesia was reported by 0.4%, 0.4%, and 0.4% of patients treated with MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. No events were reported by patients receiving placebo. In a CV outcomes trial, 0.7% of MOUNJARO-treated patients reported dysesthesia. Dysgeusia In the pool of placebo-controlled clinical trials in adults, dysgeusia was reported by 0.1% of MOUNJARO-treated patients and 0% of placebo-treated patients. Laboratory Abnormalities Amylase and Lipase Increase In the pool of placebo-controlled clinical trials in adults, treatment with MOUNJARO resulted in mean increases from baseline in serum pancreatic amylase concentrations of 33% to 38% and serum lipase concentrations of 31% to 42%. Placebo-treated patients had a mean increase from baseline in pancreatic amylase of 4% and no changes were observed in lipase. The clinical significance of elevations in lipase or amylase with MOUNJARO is unknown in the absence of other signs and symptoms of pancreatitis. In a CV outcomes trial, treatment with MOUNJARO resulted in mean increases from baseline in pancreatic amylase of 29% and lipase of 28%. 6.2 Postmarketing Experience The following adverse reactions have been reported during post-approval use of MOUNJARO. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Hypersensitivity : anaphylaxis, angioedema Gastrointestinal : acute pancreatitis, hemorrhagic and necrotizing pancreatitis sometimes resulting in death, ileus, intestinal obstruction, severe constipation including fecal impaction Pulmonary : Pulmonary aspiration has occurred in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation Renal : acute renal failure or worsening of chronic renal failure, sometimes requiring hemodialysis Skin and Subcutaneous Tissue : alopecia

Clinical studies

14 CLINICAL STUDIES 14.1 Overview of Clinical Studies The effectiveness of MOUNJARO as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus was established in five trials. In these trials, MOUNJARO was studied as monotherapy (SURPASS-1); as an add-on to metformin, sulfonylureas, and/or sodium-glucose co-transporter 2 inhibitors (SGLT2 inhibitors) (SURPASS-2, -3, and -4); and in combination with basal insulin with or without metformin (SURPASS-5). In these trials, MOUNJARO (5 mg, 10 mg, and 15 mg given subcutaneously once weekly) was compared with placebo, semaglutide 1 mg, insulin degludec, and/or insulin glargine [see Clinical Studies ( 14.2 , 14.3 , 14.4 )] . In adult patients with type 2 diabetes mellitus, treatment with MOUNJARO produced a statistically significant reduction from baseline in HbA1c compared to placebo. The effectiveness of MOUNJARO was not impacted by age, gender, race, ethnicity, region, or by baseline BMI, HbA1c, diabetes duration, or renal function. MOUNJARO 5 mg and 10 mg was studied in pediatric patients 10 years of age and older with type 2 diabetes in combination with metformin and/or basal insulin [see Clinical Studies ( 14.5 )] . 14.2 Monotherapy Use of MOUNJARO in Adult Patients with Type 2 Diabetes Mellitus SURPASS-1 (NCT03954834) was a 40-week double-blind trial that randomized 478 adult patients with type 2 diabetes mellitus with inadequate glycemic control with diet and exercise to subcutaneous MOUNJARO 5 mg, MOUNJARO 10 mg, MOUNJARO 15 mg, or placebo once weekly. Patients had a mean age of 54 years, and 52% were men. The mean duration of type 2 diabetes mellitus was 4.7 years, and the mean BMI was 32 kg/m 2 . Overall, 36% were White, 35% were Asian, 25% were American Indians/Alaska Natives, and 5% were Black or African American; 43% identified as Hispanic or Latino ethnicity. Monotherapy with MOUNJARO 5 mg, 10 mg and 15 mg once weekly for 40 weeks resulted in a statistically significant reduction in HbA1c compared with placebo (see Table 4 ). Table 4: Results at Week 40 in a Trial of MOUNJARO as Monotherapy in Adult Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control with Diet and Exercise a The modified intent-to-treat population consists of all randomly assigned participants who were exposed to at least 1 dose of study drug. Patients who discontinued study treatment because they did not meet study enrollment criteria were excluded. During the trial, rescue medication (additional antihyperglycemic medication) was initiated by 25%, 2%, 3%, and 2% of patients randomized to placebo, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. At Week 40 the HbA1c data were missing for 12%, 6%, 7%, and 14% of patients randomized to placebo, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. Missing Week 40 data were imputed using placebo-based multiple imputation. b Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors. c p<0.001 (two-sided) for superiority versus placebo, adjusted for multiplicity. d Analyzed using logistic regression adjusted for baseline value and other stratification factors. Placebo MOUNJARO 5 mg MOUNJARO 10 mg MOUNJARO 15 mg Modified Intent-to-Treat (mITT) Population (N) a 113 121 121 120 HbA1c (%) Baseline (mean) 8.1 8.0 7.9 7.9 Change at Week 40 b -0.1 -1.8 -1.7 -1.7 Difference from placebo b (95% CI) -- -1.7 c (-2.0, -1.4) -1.6 c (-1.9, -1.3) -1.6 c (-1.9, -1.3) Patients (%) achieving HbA1c <7% d 23 82 c 85 c 78 c Fasting Serum Glucose (mg/dL) Baseline (mean) 155 154 153 154 Change at Week 40 b 4 -40 -40 -39 Difference from placebo b (95% CI) -- -43 c (-55, -32) -43 c (-55, -32) -42 c (-54, -30) Body Weight (kg) Baseline (mean) 84.5 87.0 86.2 85.5 Change at Week 40 b -1.0 -6.3 -7.0 -7.8 Difference from placebo b (95% CI) -- -5.3 c (-6.8, -3.9) -6.0 c (-7.4, -4.6) -6.8 c (-8.3, -5.4) 14.3 MOUNJARO Use in Combination with Metformin, Sulfonylureas, and/or SGLT2 Inhibitors in Adult Patients with Type 2 Diabetes Mellitus Add-on to metformin SURPASS-2 (NCT03987919) was a 40-week open-label trial (double-blind with respect to MOUNJARO dose assignment) that randomized 1,879 adult patients with type 2 diabetes mellitus with inadequate glycemic control on stable doses of metformin alone to the addition of subcutaneous MOUNJARO 5 mg, MOUNJARO 10 mg, or MOUNJARO 15 mg once weekly or subcutaneous semaglutide 1 mg once weekly. Patients had a mean age of 57 years and 47% were men. The mean duration of type 2 diabetes mellitus was 8.6 years, and the mean BMI was 34 kg/m 2 . Overall, 83% were White, 4% were Black or African American, and 1% were Asian; 70% identified as Hispanic or Latino ethnicity. Treatment with MOUNJARO 10 mg and 15 mg once weekly for 40 weeks resulted in a statistically significant reduction in HbA1c compared with semaglutide 1 mg once weekly (see Table 5 and Figure 2 ). Table 5: Results at Week 40 in a Trial of MOUNJARO versus Semaglutide 1 mg in Adult Patients with Type 2 Diabetes Mellitus Added to Metformin a The modified intent-to-treat population consists of all randomly assigned participants who were exposed to at least 1 dose of study drug. Patients who discontinued study treatment because they did not meet study enrollment criteria were excluded. During the trial, rescue medication (additional antihyperglycemic medication) was initiated by 3%, 2%, 1%, and 1% of patients randomized to semaglutide 1 mg, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. At Week 40 the HbA1c endpoint was missing for 5%, 4%, 5%, and 5% of patients randomized to semaglutide 1 mg, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. Missing Week 40 data were imputed using multiple imputation with retrieved dropout. b Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors. c p<0.05 (two-sided) for superiority versus semaglutide, adjusted for multiplicity. d p<0.001 (two-sided) for superiority versus semaglutide, adjusted for multiplicity. e Analyzed using logistic regression adjusted for baseline value and other stratification factors. f p<0.01 (two-sided) for superiority versus semaglutide, adjusted for multiplicity. Semaglutide 1 mg MOUNJARO 5 mg MOUNJARO 10 mg MOUNJARO 15 mg Modified Intent-to-Treat (mITT) Population (N) a 468 470 469 469 HbA1c (%) Baseline (mean) 8.3 8.3 8.3 8.3 Change at Week 40 b -1.9 -2.0 -2.2 -2.3 Difference from semaglutide b (95% CI) -- -0.2 c (-0.3, -0.0) -0.4 d (-0.5, -0.3) -0.5 d (-0.6, -0.3) Patients (%) achieving HbA1c <7% e 79 82 86 f 86 f Fasting Serum Glucose (mg/dL) Baseline (mean) 171 174 174 172 Change at Week 40 b -49 -55 -59 -60 Body Weight (kg) Baseline (mean) 93.7 92.5 94.8 93.8 Change at Week 40 b -5.7 -7.6 -9.3 -11.2 Difference from semaglutide b (95% CI) -- -1.9 c (-2.8, -1.0) -3.6 d (-4.5, -2.7) -5.5 d (-6.4, -4.6) Figure 2: Mean HbA1c (%) Over Time - Baseline to Week 40 Number of patients MOUNJARO 5mg 470 451 470 MOUNJARO 10mg 469 445 469 MOUNJARO 15mg 469 447 469 Semaglutide 1mg 468 443 468 Note: Displayed results are from modified Intent-to-Treat Full Analysis Set. (1) Observed mean value from Week 0 to Week 40, and (2) least-squares mean ± standard error at Week 40 multiple imputation (MI). Figure 2 Add-on to metformin with or without SGLT2 inhibitor SURPASS-3 (NCT03882970) was a 52-week open-label trial that randomized 1,444 adult patients with type 2 diabetes mellitus with inadequate glycemic control on stable doses of metformin with or without SGLT2 inhibitor to the addition of subcutaneous MOUNJARO 5 mg, MOUNJARO 10 mg, MOUNJARO 15 mg once weekly, or insulin degludec 100 units/mL once daily. In this trial, 32% of patients were on SGLT2 inhibitor. Insulin degludec was initiated at 10 units once daily and adjusted weekly throughout the trial using a treat-to-target algorithm based on self-measured fasting blood glucose values. At Week 52, 26% of patients randomized to insulin degludec achieved the fasting serum glucose target of <90 mg/dL, and the mean daily insulin degludec dose was 49 U (0.5 U per kilogram). Patients had a mean age of 57 years, and 56% were men. The mean duration of type 2 diabetes mellitus was 8.4 years, and the mean baseline BMI was 34 kg/m 2 . Overall, 91% were White, 3% were Black or African American, and 5% were Asian; 29% identified as Hispanic or Latino ethnicity. Treatment with MOUNJARO 10 mg and 15 mg once weekly for 52 weeks resulted in a statistically significant reduction in HbA1c compared with daily insulin degludec (see Table 6 ). Table 6: Results at Week 52 in a Trial of MOUNJARO versus Insulin Degludec in Adult Patients with Type 2 Diabetes Mellitus Added to Metformin with or without SGLT2 Inhibitor a The modified intent-to-treat population consists of all randomly assigned participants who were exposed to at least 1 dose of study drug. Patients who discontinued study treatment because they did not meet study enrollment criteria were excluded. During the trial, rescue medication (additional antihyperglycemic medication) was initiated by 1%,1%, 1%, and 2% of patients randomized to insulin degludec, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. At Week 52 the HbA1c endpoint was missing for 9%, 6%, 10%, and 5% of patients randomized to insulin degludec, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. Missing Week 52 data were imputed using multiple imputation with retrieved dropout. b Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors. c p<0.001 (two-sided) for superiority versus insulin degludec, adjusted for multiplicity. d Analyzed using logistic regression adjusted for baseline value and other stratification factors. Insulin Degludec MOUNJARO 5 mg MOUNJARO 10 mg MOUNJARO 15 mg Modified Intent-to-Treat (mITT) a Population (N) 359 358 360 358 HbA1c (%) Baseline (mean) 8.1 8.2 8.2 8.2 Change at Week 52 b -1.3 -1.9 -2.0 -2.1 Difference from insulin degludec b (95% CI) -- -0.6 c (-0.7, -0.5) -0.8 c (-0.9, -0.6) -0.9 c (-1.0, -0.7) Patients (%) achieving HbA1c <7% d 58 79 c 82 c 83 c Fasting Serum Glucose (mg/dL) Baseline (mean) 167 172 170 168 Change at Week 52 b -51 -47 -50 -54 Body Weight (kg) Baseline (mean) 94.0 94.4 93.8 94.9 Change at Week 52 b 1.9 -7.0 -9.6 -11.3 Difference from insulin degludec b (95% CI) -- -8.9 c (-10.0, -7.8) -11.5 c (-12.6, -10.4) -13.2 c (-14.3, -12.1) Add-on to 1-3 oral anti-hyperglycemic agents (metformin, sulfonylurea, or SGLT-2 inhibitor) SURPASS-4 (NCT03730662) was a 104-week open-label trial (52-week primary endpoint) that randomized 2002 adult patients with type 2 diabetes mellitus with increased CV risk to subcutaneous MOUNJARO 5 mg, MOUNJARO 10 mg, MOUNJARO 15 mg once weekly, or insulin glargine 100 units/mL once daily (1:1:1:3 ratio) on a background of metformin (95%) and/or sulfonylureas (54%) and/or SGLT2 inhibitors (25%). Patients had a mean age of 64 years, and 63% were men. The mean duration of type 2 diabetes mellitus was 11.8 years, and the mean baseline BMI was 33 kg/m 2 . Overall, 82% were White, 4% were Black or African American, and 4% were Asian; 48% identified as Hispanic or Latino ethnicity. Across all treatment groups, 87% had a history of CV disease. At baseline, eGFR was ≥90 mL/min/1.73 m 2 in 43%, 60 to 90 mL/min/1.73 m 2 in 40%, 45 to 60 mL/min/1.73 m 2 in 10%, and 30 to 45 mL/min/1.73 m 2 in 6% of patients. Insulin glargine was initiated at 10 U once daily and adjusted weekly throughout the trial using a treat-to-target algorithm based on self-measured fasting blood glucose values. At Week 52, 30% of patients randomized to insulin glargine achieved the fasting serum glucose target of <100 mg/dL, and the mean daily insulin glargine dose was 44 U (0.5 U per kilogram). Treatment with MOUNJARO 10 mg and 15 mg once weekly for 52 weeks resulted in a statistically significant reduction in HbA1c compared with insulin glargine once daily (see Table 7 ). Table 7: Results at Week 52 in a Trial of MOUNJARO versus Insulin Glargine in Adult Patients with Type 2 Diabetes Mellitus Added to Metformin and/or Sulfonylurea and/or SGLT2 Inhibitor a The modified intent-to-treat population consists of all randomly assigned participants who were exposed to at least 1 dose of study drug. Patients who discontinued study treatment because they did not meet study enrollment criteria were excluded. During the trial, rescue medication (additional antihyperglycemic medication) was initiated by 1%, 0%, 0%, and 1% of patients randomized to insulin glargine, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. At Week 52 the HbA1c endpoint was missing for 9%, 9%, 6%, and 4% of patients randomized to insulin glargine, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. Missing Week 52 data were imputed using multiple imputation with retrieved dropout. b Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors. c p<0.001 (two-sided) for superiority versus insulin glargine, adjusted for multiplicity. d Analyzed using logistic regression adjusted for baseline value and other stratification factors. Insulin Glargine MOUNJARO 5 mg MOUNJARO 10 mg MOUNJARO 15 mg Modified Intent-to-Treat (mITT) Population (N) a 998 328 326 337 HbA1c (%) Baseline (mean) 8.5 8.5 8.6 8.5 Change at Week 52 b -1.4 -2.1 -2.3 -2.4 Difference from insulin glargine b (95% CI) -- -0.7 c (-0.9, -0.6) -0.9 c (-1.1, -0.8) -1.0 c (-1.2, -0.9) Patients (%) achieving HbA1c <7% d 49 75 c 83 c 85 c Fasting Serum Glucose (mg/dL) Baseline (mean) 168 172 176 174 Change at Week 52 b -49 -44 -50 -55 Body Weight (kg) Baseline (mean) 90.2 90.3 90.6 90.0 Change at Week 52 b 1.7 -6.4 -8.9 -10.6 Difference from insulin glargine b (95% CI) -- -8.1 c (-8.9, -7.3) -10.6 c (-11.4, -9.8) -12.2 c (-13.0, -11.5) 14.4 MOUNJARO Use in Combination with Basal Insulin with or without Metformin in Adult Patients with Type 2 Diabetes Mellitus SURPASS-5 (NCT04039503) was a 40-week double-blind trial that randomized 475 adult patients with type 2 diabetes mellitus with inadequate glycemic control on insulin glargine 100 units/mL, with or without metformin, to subcutaneous MOUNJARO 5 mg, MOUNJARO 10 mg, MOUNJARO 15 mg once weekly, or placebo. The dose of background insulin glargine was adjusted using a treat-to-target algorithm based on self-measured fasting blood glucose values, targeting <100 mg/dL. Patients had a mean age of 61 years, and 56% were men. The mean duration of type 2 diabetes mellitus was 13.3 years, and the mean baseline BMI was 33 kg/m 2 . Overall, 80% were White, 1% were Black or African American, and 18% were Asian; 5% identified as Hispanic or Latino ethnicity. The mean dose of insulin glargine at baseline was 34, 32, 35, and 33 units/day for patients receiving MOUNJARO 5 mg, 10 mg, 15 mg, and placebo, respectively. At randomization, the initial insulin glargine dose in patients with HbA1c ≤8.0% was reduced by 20%. At week 40, mean dose of insulin glargine was 38, 36, 29, and 59 units/day for patients receiving MOUNJARO 5 mg, 10 mg, 15 mg, and placebo, respectively. Treatment with MOUNJARO 5 mg once weekly, 10 mg once weekly and 15 mg once weekly for 40 weeks resulted in a statistically significant reduction in HbA1c compared with placebo (see Table 8 ). Table 8: Results at Week 40 in a Trial of MOUNJARO Added to Basal Insulin with or without Metformin in Adult Patients with Type 2 Diabetes Mellitus a The modified intent-to-treat population consists of all randomly assigned participants who were exposed to at least 1 dose of study drug. Patients who discontinued study treatment because they did not meet study enrollment criteria were excluded. During the trial, rescue medication (additional antihyperglycemic medication) was initiated by 4%, 1%, 0%, and 1% of patients randomized to placebo, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. At Week 40 the HbA1c endpoint was missing for 2%, 6%, 3%, and 7% of patients randomized to placebo, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. Missing Week 40 data were imputed using placebo-based multiple imputation. b Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors. c p<0.001 (two-sided) for superiority versus placebo, adjusted for multiplicity. d Analyzed using logistic regression adjusted for baseline value and other stratification factors. Placebo MOUNJARO 5 mg MOUNJARO 10 mg MOUNJARO 15 mg Modified Intent-to-Treat (mITT) Population (N) a 119 116 118 118 HbA1c (%) Baseline (mean) 8.4 8.3 8.4 8.2 Change at Week 40 b -0.9 -2.1 -2.4 -2.3 Difference from placebo b (95% CI) -- -1.2 c (-1.5, -1.0) -1.5 c (-1.8, -1.3) -1.5 c (-1.7, -1.2) Patients (%) achieving HbA1c <7% d 35 87 c 90 c 85 c Fasting Serum Glucose (mg/dL) Baseline (mean) 164 163 163 160 Change at Week 40 b -39 -58 -64 -63 Difference from placebo b (95% CI) -- -19 c (-27, -11) -25 c (-32, -17) -23 c (-31, -16) Body Weight (kg) Baseline (mean) 94.2 95.8 94.6 96.0 Change at Week 40 b 1.6 -5.4 -7.5 -8.8 Difference from placebo b (95% CI) -- -7.1 c (-8.7, -5.4) -9.1 c (-10.7, -7.5) -10.5 c (-12.1, -8.8) 14.5 MOUNJARO Use in Combination with Metformin or Basal Insulin, or Both in Pediatric Patients 10 Years of Age and Older with Type 2 Diabetes Mellitus SURPASS-PEDS (NCT05260021) was a 30-week double-blind, placebo-controlled trial with a 22-week open-label extension that randomized 99 pediatric patients 10 years of age and older with type 2 diabetes mellitus with inadequate glycemic control on metformin (69%), or basal insulin (8%), or both (23%) to receive subcutaneous MOUNJARO 5 mg, MOUNJARO 10 mg, or placebo once weekly as add-on therapy. Patients had a mean age of 15 years, and 61% were female. The mean duration of type 2 diabetes mellitus was 2.4 years, mean HbA1c was 8.0%, mean weight was 97 kg, and the mean baseline BMI was 35 kg/m 2 . Overall, 58% were White, 11% were Black or African American, 6% were Asian, 20% were American Indian or Alaska Native, and 5% were other races; 66% identified as Hispanic or Latino ethnicity. Treatment with MOUNJARO 5 mg once weekly and 10 mg once weekly for 30 weeks, both pooled and individually, resulted in a statistically significant reduction in HbA1c compared with placebo (see Table 9 ). Table 9: Results at Week 30 in a Trial of MOUNJARO Added to Metformin or Basal Insulin, or Both in Pediatric Patients 10 Years of Age and Older with Type 2 Diabetes Mellitus a The modified intent-to-treat population consists of all randomly assigned participants who were exposed to at least 1 dose of study drug. During the trial, rescue medication (additional antihyperglycemic medication) was initiated by 6%, 0%, and 0% of patients randomized to placebo, MOUNJARO 5 mg, and 10 mg, respectively. At Week 30 the HbA1c endpoint was missing for 6%, 9%, and 18% of patients randomized to placebo, MOUNJARO 5 mg, and 10 mg, respectively. Missing Week 30 data were imputed using multiple imputation with placebo wash-out or with assumption of missing at random. b Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors. c p<0.001 (two-sided) for superiority versus placebo, adjusted for multiplicity. d Response in (%) is calculated by combining proportion of participants achieving target in imputed datasets using Rubin's rule. e p<0.01 (two-sided) for superiority versus placebo, adjusted for multiplicity. f Any missing values at baseline were imputed as missing at random. Placebo MOUNJARO 5 mg MOUNJARO 10 mg MOUNJARO 5 mg/10 mg pooled Modified Intent-to-Treat (mITT) Population (N) a 34 32 33 65 HbA1c (%) Baseline (mean) 8.0 8.2 7.9 8.1 Change at Week 30 b -0.2 -1.9 -2.2 -2.0 Difference from placebo b (95% CI) -- -1.7 c (-2.4, -1.0) -2.0 c (-2.7, -1.3) -1.8 c (-2.4, -1.2) Patients (%) with HbA1c ≤6.5% at Week 30 d 28 68 c 81 c 75 c Fasting Serum Glucose (mg/dL) Baseline (mean) 156 f 148 f 152 f 150 f Change at Week 30 b -5 -35 -51 -43 Difference from placebo b (95% CI) -- -30 e (-53, -8) -46 c (-68, -24) -38 c (-57, -19) BMI (kg/m 2 ) Baseline (mean) 34.7 33.9 37.7 35.8 Percent Change at Week 30 b -0.5 -6.9 -10.8 -8.8 Difference from placebo (%) b (95% CI) -- -6.4 c (-9.5, -3.2) -10.3 c (-13.5, -7.1) -8.3 c (-11.0, -5.6) 14.6 Cardiovascular Outcomes Trial of MOUNJARO in Adults with Type 2 Diabetes Mellitus and Established Cardiovascular Disease SURPASS-CVOT (NCT04255433) was a Phase 3, event-driven, multicenter, international, randomized, double-blind, active comparator controlled, parallel-group study. In this trial, 13,299 patients with inadequately controlled type 2 diabetes mellitus and established CV disease were randomized to once weekly subcutaneous MOUNJARO (up to 15 mg) versus once weekly subcutaneous dulaglutide (1.5 mg), a GLP-1 receptor agonist indicated for glycemic control and to reduce the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes mellitus who have established CV disease or multiple CV risk factors. MOUNJARO was initiated at a dosage of 2.5 mg once weekly and increased by 2.5 mg every 4 weeks to a maximum dosage of 15 mg once weekly or the maximum tolerated dose. The dose of dulaglutide was initiated and maintained at 1.5 mg once weekly. The primary endpoint was the time to first occurrence of a three-part composite MACE outcome of CV death, MI, or stroke (MACE-3). Patients eligible to enroll in the trial had type 2 diabetes mellitus and established CV disease, were 40 years of age or older, had a HbA1c of ≥7.0% and ≤10.5%, and a BMI ≥ 25 kg/m 2 . The mean age was 64 years, the mean duration of type 2 diabetes mellitus was 15 years, the mean HbA1c concentration was 8.4%, and the mean BMI was 33 kg/m 2 . Overall, 71% of patients enrolled were male; 82% were White, 2% were Black or African American, and 9% were Asian; 30% identified Hispanic or Latino ethnicity. Patients reported the following types of CV disease at baseline: coronary artery disease (65%); prior coronary revascularization (57%); prior MI (47%); peripheral arterial disease (25%); prior lower extremity arterial revascularization (6%); prior stroke (19%); prior carotid revascularization (3%); and prior heart failure (20%). Of patients enrolled in the study, 20% had diabetic neuropathy, 2% had proliferative diabetic retinopathy, and 29% had non-proliferative diabetic retinopathy. The percentage of patients with an eGFR < 60 mL/min/1.73 m 2 was 23%. The most common antihyperglycemic medications taken at baseline were: metformin (81%), sodium-glucose cotransporter-2 (SGLT-2) inhibitors (31%), sulfonylureas (22%), and insulins (49%). At baseline CV disease and CV risk factors were managed with: statins (86%), antiplatelet therapies (83%), beta blockers (65%), angiotensin-converting enzyme (ACE) inhibitors (40%), and angiotensin receptor blockers (40%). During the trial, investigators were to modify anti-hyperglycemic and CV medications to achieve local standard of care treatment targets with respect to blood glucose, lipids, and blood pressure. Over a median follow-up of 210.1 weeks, MOUNJARO was non-inferior to dulaglutide for reducing the occurrence of MACE-3. The estimated hazard ratio for time to first MACE was 0.92 (95.3% CI: 0.83, 1.01) for MOUNJARO compared to dulaglutide. Superiority to dulaglutide was not established. In this trial, 98% of participants had a complete assessment for the primary endpoint and 99.7% had vital status established. Refer to Figure 3 and Table 10 . Figure 3: Kaplan-Meier Curve: Time to First Occurrence of a MACE-3 (CV death, non-fatal MI, or non-fatal stroke) in the SURPASS-CVOT Trial Table 10: Treatment Effect for MACE and All Cause Death, All Randomized and Treated Participants, Median Study Observation Time 210.1 weeks a 95.3% confidence interval for the MACE-3 composite endpoint of CV death, non-fatal MI, or non-fatal stroke b Cox-proportional hazards models with treatment as a factor and stratified for SGLT2i use. c p=0.007 for noninferiority of MOUNJARO to dulaglutide d Not controlled for family-wise type I error rate Dulaglutide N=6,647 (%) MOUNJARO N=6,647 (%) Hazard ratio vs Dulaglutide (95% CI) MACE-3 (Composite of time to first occurrence of CV death, non-fatal MI, or non-fatal stroke) a,b,c 863 (13.0) 803 (12.1) 0.92 (0.83, 1.01) CV Death d 409 (6.2) 367 (5.5) 0.89 (0.77, 1.02) Non-Fatal MI d 310 (4.7) 292 (4.4) 0.93 (0.80, 1.09) Non-Fatal Stroke d 221 (3.3) 215 (3.2) 0.97 (0.80, 1.16) Fatal or Non-Fatal MI d 358 (5.4) 313 (4.7) 0.87 (0.74, 1.01) Fatal or Non-Fatal Stroke d 249 (3.7) 229 (3.4) 0.91 (0.76, 1.09) All-Cause Death d 670 (10.1) 567 (8.5) 0.84 (0.75, 0.94) Reductions from baseline in HbA1c and body weight were observed with MOUNJARO and dulaglutide treatment at Month 36. Figure 3

Zepbound / ZEPBOUND / Zepbound KwikPen

SUBCUTANEOUS · Eli Lilly and Company

Label effective · version 40Retrieved · Nov 17, 2026 UTCFull label on DailyMed (dailymed.nlm.nih.gov)Indexed source record (api.fda.gov)
Read indexed warnings and label text

Boxed warning

WARNING: RISK OF THYROID C-CELL TUMORS In rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether ZEPBOUND causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined [see Warnings and Precautions ( 5.1 ) and Nonclinical Toxicology ( 13.1 )]. ZEPBOUND is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Contraindications ( 4 )] . Counsel patients regarding the potential risk for MTC with the use of ZEPBOUND and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with ZEPBOUND [see Contraindications ( 4 ) and Warnings and Precautions ( 5.1 )]. WARNING: RISK OF THYROID C-CELL TUMORS See full prescribing information for complete boxed warning. In rats, tirzepatide causes thyroid C-cell tumors. It is unknown whether ZEPBOUND causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined ( 5.1 , 13.1 ). ZEPBOUND is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and symptoms of thyroid tumors ( 4 , 5.1 ).

Contraindications

4 CONTRAINDICATIONS ZEPBOUND is contraindicated in patients with: A personal or family history of MTC or in patients with MEN 2 [see Warnings and Precautions ( 5.1 )] . Known serious hypersensitivity to tirzepatide or any of the excipients in ZEPBOUND. Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with tirzepatide [see Warnings and Precautions ( 5.6 ) and Adverse Reactions ( 6.2 )] . Personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2 ( 4 ) Known serious hypersensitivity to tirzepatide or any of the excipients in ZEPBOUND ( 4 )

Indications and uses

1 INDICATIONS AND USAGE ZEPBOUND ® is indicated in combination with a reduced-calorie diet and increased physical activity: to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity. ZEPBOUND is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated in combination with a reduced-calorie diet and increased physical activity: to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. ( 1 ) to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity. ( 1 ) Limitations of Use: Coadministration with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended. ( 1 ) Limitations of Use ZEPBOUND contains tirzepatide. Coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.

Dosing and administration

2 DOSAGE AND ADMINISTRATION Recommended Dose Escalation Schedule The recommended starting dosage is 2.5 mg injected subcutaneously once weekly for 4 weeks. Increase the dosage in 2.5 mg increments after at least 4 weeks until recommended maintenance dosage is achieved. ( 2.1 ) Consider treatment response and tolerability when selecting the maintenance dosage. ( 2.1 ) Recommended Maintenance and Maximum Dosage Weight Reduction and Long-Term Maintenance: 5 mg, 10 mg, or 15 mg injected subcutaneously once weekly. ( 2.2 ) Obstructive Sleep Apnea: 10 mg or 15 mg injected subcutaneously once weekly. ( 2.2 ) Maximum Recommended Dosage: 15 mg injected subcutaneously once weekly. ( 2.2 ) Administration Instructions Refer to the Full Prescribing Information for additional important administration instructions about ZEPBOUND presentations. ( 2.4 ) 2.1 Recommended Dose Escalation Schedule The recommended starting dosage of ZEPBOUND for all indications is 2.5 mg injected subcutaneously once weekly for 4 weeks. The 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage. Follow the dosage escalation below for all indications to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions ( 5.2 ) and Adverse Reactions ( 6.1 )] . After 4 weeks, increase the dosage to 5 mg injected subcutaneously once weekly. The dosage may be increased in 2.5 mg increments, after at least 4 weeks on the current dose [see Dosage and Administration ( 2.2 )] . Consider treatment response and tolerability when selecting the maintenance dosage. If patients do not tolerate a maintenance dosage, consider a lower maintenance dosage. 2.2 Recommended Maintenance and Maximum Dosage Recommended Maintenance Dosage Weight Reduction and Long-Term Maintenance The recommended maintenance dosage is 5 mg, 10 mg, or 15 mg, injected subcutaneously once weekly. OSA The recommended maintenance dosage is 10 mg or 15 mg injected subcutaneously once weekly. Maximum Recommended Dosage The maximum dosage of ZEPBOUND for all indications is 15 mg injected subcutaneously once weekly. 2.3 Recommendations Regarding Missed Dose If a dose is missed, instruct patients to administer ZEPBOUND as soon as possible within 4 days (96 hours) after the missed dose. If more than 4 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day. In each case, patients can then resume their regular once weekly dosing schedule. The day of weekly administration can be changed, if necessary, as long as the time between the two doses is at least 3 days (72 hours). 2.4 Important Administration Instructions Inform patients and their caregiver(s) which ZEPBOUND presentation (e.g., vial, prefilled single-dose pen, single-patient-use KwikPen) they will receive and ensure they receive training appropriate for that specific presentation. If the prescribed ZEPBOUND presentation changes, ensure patients and caregivers receive appropriate training and instruct them to consult the Instructions for Use for the newly prescribed presentation. Prior to initiation, train patients and their caregiver(s) on proper injection technique for the prescribed ZEPBOUND presentation [see Instructions for Use ] . After training, a patient may self-inject ZEPBOUND if the healthcare provider determines that it can be properly administered, except for the following: ZEPBOUND KwikPen is not recommended for self-administration by those who are visually impaired. Instruct patients using ZEPBOUND vials to use a syringe appropriate for dose administration (e.g., a 1 mL syringe capable of measuring a 0.5 mL or 0.6 mL dose) and always use a new syringe and needle for each injection. Inspect ZEPBOUND visually before use. It should appear clear and colorless to slightly yellow. Do not use ZEPBOUND if particulate matter or discoloration is seen. Administer ZEPBOUND in combination with a reduced-calorie diet and increased physical activity. Administer ZEPBOUND once weekly at any time of day, with or without meals. Inject ZEPBOUND subcutaneously in the abdomen, thigh, or another person should inject in the back of the upper arm. Rotate injection sites with each dose.

Warnings and precautions

5 WARNINGS AND PRECAUTIONS Severe Gastrointestinal Adverse Reactions: Use has been associated with gastrointestinal adverse reactions, sometimes severe. ZEPBOUND is not recommended in patients with severe gastroparesis. ( 5.2 ) Acute Kidney Injury Due to Volume Depletion: Monitor renal function in patients reporting adverse reactions that could lead to volume depletion. ( 5.3 ) Acute Gallbladder Disease: Has been reported in clinical trials. If cholecystitis is suspected, gallbladder studies and clinical follow-up are indicated. ( 5.4 ) Acute Pancreatitis: Has been observed in patients treated with GLP-1 receptor agonists, or ZEPBOUND. Discontinue if pancreatitis is suspected. ( 5.5 ) Hypersensitivity Reactions: Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported postmarketing with tirzepatide. If suspected, advise patients to promptly seek medical attention and discontinue ZEPBOUND. ( 5.6 ) Hypoglycemia: Concomitant use with insulin or an insulin secretagogue may increase the risk of hypoglycemia, including severe hypoglycemia. Reducing dose of insulin or insulin secretagogue may be necessary. Inform all patients of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia. ( 5.7 ) Diabetic Retinopathy Complications in Patients with Type 2 Diabetes Mellitus: Monitor patients with a history of diabetic retinopathy for progression. ( 5.8 ) Pulmonary Aspiration During General Anesthesia or Deep Sedation: Has been reported in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures. Instruct patients to inform healthcare providers of any planned surgeries or procedures. ( 5.9 ) Never share a ZEPBOUND KwikPen between patients, even if the pen needle is changed. ( 5.10 ) 5.1 Risk of Thyroid C-Cell Tumors In rats, tirzepatide caused a dose-dependent and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) in a 2-year study at clinically relevant plasma exposures [see Nonclinical Toxicology ( 13.1 )] . It is unknown whether ZEPBOUND causes thyroid C-cell tumors, including MTC, in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined. ZEPBOUND is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2. Counsel patients regarding the potential risk for MTC with the use of ZEPBOUND and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with ZEPBOUND. Such monitoring may increase the risk of unnecessary procedures, due to the low test specificity for serum calcitonin and a high background incidence of thyroid disease. Significantly elevated serum calcitonin values may indicate MTC and patients with MTC usually have calcitonin values >50 ng/L. If serum calcitonin is measured and found to be elevated, the patient should be further evaluated. Patients with thyroid nodules noted on physical examination or neck imaging should also be further evaluated. 5.2 Severe Gastrointestinal Adverse Reactions Use of ZEPBOUND has been associated with gastrointestinal adverse reactions, sometimes severe [see Adverse Reactions ( 6 )] . In a pool of two ZEPBOUND clinical trials for weight reduction (Studies 1 and 2), severe gastrointestinal adverse reactions were reported more frequently among patients receiving ZEPBOUND (5 mg 1.7%, 10 mg 2.5%, 15 mg 3.1%) than placebo (1%). Similar rates of severe gastrointestinal adverse reactions were observed in ZEPBOUND clinical trials for weight reduction and in ZEPBOUND clinical trials for OSA. Severe gastrointestinal adverse reactions have also been reported postmarketing with GLP-1 receptor agonists. ZEPBOUND is not recommended in patients with severe gastroparesis. 5.3 Acute Kidney Injury Due to Volume Depletion There have been postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with GLP-1 receptor agonists, or ZEPBOUND [see Adverse Reactions ( 6.2 )] . The majority of the reported events occurred in patients who experienced gastrointestinal adverse reactions leading to dehydration such as nausea, vomiting, or diarrhea [see Adverse Reactions ( 6.1 )] . Monitor renal function in patients reporting adverse reactions to ZEPBOUND that could lead to volume depletion, especially during dosage initiation and escalation of ZEPBOUND. 5.4 Acute Gallbladder Disease Treatment with ZEPBOUND and GLP-1 receptor agonists is associated with an increased occurrence of acute gallbladder disease. In a pool of two ZEPBOUND clinical trials for weight reduction (Studies 1 and 2), cholelithiasis was reported in 1.1% of ZEPBOUND-treated patients and 1% of placebo-treated patients, cholecystitis was reported in 0.7% of ZEPBOUND-treated patients and 0.2% of placebo-treated patients, and cholecystectomy was reported in 0.2% of ZEPBOUND-treated patients and no placebo-treated patients. Acute gallbladder events were associated with weight reduction. Similar rates of cholelithiasis were reported in ZEPBOUND clinical trials for weight reduction and in ZEPBOUND trials for OSA. If cholecystitis is suspected, gallbladder diagnostic studies and appropriate clinical follow-up are indicated. 5.5 Acute Pancreatitis Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, or ZEPBOUND [see Adverse Reactions ( 6 )] . After initiation of ZEPBOUND, observe patients carefully for signs and symptoms of acute pancreatitis which may include persistent or severe abdominal pain (sometimes radiating to the back) and which may or may not be accompanied by nausea or vomiting. If pancreatitis is suspected, discontinue ZEPBOUND and initiate appropriate management. 5.6 Hypersensitivity Reactions There have been postmarketing reports of serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) in patients treated with tirzepatide. In a pool of two ZEPBOUND clinical studies for weight reduction (Studies 1 and 2), 0.1% of ZEPBOUND-treated patients had severe hypersensitivity reactions compared to no placebo-treated patients. Similar rates of severe hypersensitivity reactions were observed in ZEPBOUND clinical trials for weight reduction and in ZEPBOUND trials for OSA. If hypersensitivity reactions occur, advise patients to promptly seek medical attention and discontinue use of ZEPBOUND. Do not use in patients with a previous serious hypersensitivity reaction to tirzepatide or any of the excipients in ZEPBOUND [see Contraindications ( 4 ) and Adverse Reactions ( 6.2 )] . Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with GLP-1 receptor agonists. Use caution in patients with a history of angioedema or anaphylaxis with a GLP-1 receptor agonist because it is unknown whether such patients will be predisposed to these reactions with ZEPBOUND. 5.7 Hypoglycemia ZEPBOUND lowers blood glucose and can cause hypoglycemia. In a trial of patients with type 2 diabetes mellitus and BMI ≥27 kg/m 2 (Study 2), hypoglycemia (plasma glucose <54 mg/dL) was reported in 4.2% of ZEPBOUND-treated patients versus 1.3% of placebo-treated patients. In this trial, patients taking ZEPBOUND in combination with an insulin secretagogue (e.g., sulfonylurea) had increased risk of hypoglycemia (10.3%) compared to ZEPBOUND-treated patients not taking a sulfonylurea (2.1%). There is also increased risk of hypoglycemia in patients treated with tirzepatide in combination with insulin [see Drug Interactions ( 7.1 )] . Hypoglycemia has also been associated with ZEPBOUND and GLP-1 receptor agonists in adults without type 2 diabetes mellitus [see Adverse Reactions ( 6.1 )] . Inform patients of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia. In patients with diabetes mellitus, monitor blood glucose prior to starting ZEPBOUND and during ZEPBOUND treatment. The risk of hypoglycemia may be lowered by a reduction in the dose of insulin or sulfonylurea (or other concomitantly administered insulin secretagogue). 5.8 Diabetic Retinopathy Complications in Patients with Type 2 Diabetes Mellitus Temporary worsening of diabetic retinopathy has been reported with rapid improvement in glucose control. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy. 5.9 Pulmonary Aspiration During General Anesthesia or Deep Sedation ZEPBOUND delays gastric emptying [see Clinical Pharmacology ( 12.2 )] . There have been rare postmarketing reports of pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations. Available data are insufficient to inform recommendations to mitigate the risk of pulmonary aspiration during general anesthesia or deep sedation in patients taking ZEPBOUND, including whether modifying preoperative fasting recommendations or temporarily discontinuing ZEPBOUND could reduce the incidence of retained gastric contents. Instruct patients to inform healthcare providers prior to any planned surgeries or procedures if they are taking ZEPBOUND. 5.10 Never Share a ZEPBOUND KwikPen Between Patients Never share ZEPBOUND KwikPen between patients, even if the pen needle is changed. Sharing poses a risk for transmission of blood-borne pathogens.

Drug interactions

7 DRUG INTERACTIONS ZEPBOUND delays gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications. ( 7.2 ) 7.1 Concomitant Use with Insulin or an Insulin Secretagogue (e.g., Sulfonylurea) ZEPBOUND lowers blood glucose. When initiating ZEPBOUND, consider reducing the dose of concomitantly administered insulin or insulin secretagogues (e.g., sulfonylureas) to reduce the risk of hypoglycemia [see Warnings and Precautions ( 5.7 )] . 7.2 Oral Medications ZEPBOUND delays gastric emptying and thereby has the potential to impact the absorption of concomitantly administered oral medications. Caution should be exercised when oral medications are concomitantly administered with ZEPBOUND. Monitor patients on oral medications dependent on threshold concentrations for efficacy and those with a narrow therapeutic index (e.g., warfarin) when concomitantly administered with ZEPBOUND. Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. Hormonal contraceptives that are not administered orally should not be affected [see Use in Specific Populations ( 8.3 ) and Clinical Pharmacology ( 12.2 , 12.3 )] .

Adverse reactions

6 ADVERSE REACTIONS The following serious adverse reactions are described below or elsewhere in the prescribing information: Risk of Thyroid C-cell Tumors [see Warnings and Precautions ( 5.1 )] Severe Gastrointestinal Adverse Reactions [see Warnings and Precautions ( 5.2 )] Acute Kidney Injury Due to Volume Depletion [see Warnings and Precautions ( 5.3 )] Acute Gallbladder Disease [see Warnings and Precautions ( 5.4 )] Acute Pancreatitis [see Warnings and Precautions ( 5.5 )] Hypersensitivity Reactions [see Warnings and Precautions ( 5.6 )] Hypoglycemia [see Warnings and Precautions ( 5.7 )] Diabetic Retinopathy Complications in Patients with Type 2 Diabetes Mellitus [see Warnings and Precautions ( 5.8 )] Pulmonary Aspiration During General Anesthesia or Deep Sedation [see Warnings and Precautions ( 5.9 )] The most common adverse reactions, reported in ≥5% of patients treated with ZEPBOUND are: nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection site reactions, fatigue, hypersensitivity reactions, eructation, hair loss, gastroesophageal reflux disease. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Adverse Reactions in Patients for Weight Reduction and Long-Term Maintenance Pool of Placebo - Controlled Weight Reduction Trials in Adults with Obesity or Overweight, with or without Type 2 Diabetes (Study 1 and Study 2) ZEPBOUND was evaluated for safety in a pool of two randomized, double-blind, placebo-controlled trials that included 2,519 adult patients with obesity or overweight treated with ZEPBOUND for up to 72 weeks and a 4-week off drug follow-up period (Study 1 and Study 2) [see Clinical Studies ( 14.1 )] . The mean age of patients was 47 years and 37% were male. The population was 72% White, 12% Asian, 8% Black or African American, and 7% American Indian or Alaska Native; 51% identified as Hispanic or Latino ethnicity. Baseline characteristics included an average BMI of 37.4 kg/m 2 , 29% with a BMI ≥40 kg/m 2 , 41% with hypertension, 37% with dyslipidemia, 25% with type 2 diabetes mellitus, 7% with obstructive sleep apnea, and 4% with cardiovascular (CV) disease. Across both trials, 4.8%, 6.3%, and 6.7% of patients treated with 5 mg, 10 mg, and 15 mg of ZEPBOUND, respectively, permanently discontinued treatment as a result of adverse reactions compared to 3.4% of patients treated with placebo. The majority of patients who discontinued ZEPBOUND due to adverse reactions did so during the first few months of treatment due to gastrointestinal adverse reactions. Common Adverse Reactions Table 1 shows common adverse reactions associated with the use of ZEPBOUND in the pool of two placebo-controlled trials for weight reduction (Study 1 and Study 2). These adverse reactions occurred more commonly with ZEPBOUND than with placebo and occurred in at least 2% of patients treated with ZEPBOUND. Table 1: Adverse Reactions (≥2% and Greater than Placebo) in ZEPBOUND-Treated Adults with Obesity or Overweight in Weight Reduction and Long-term Maintenance Trials (Study 1 and Study 2) a Includes diarrhea, frequent bowel movements. b Includes constipation, feces hard. c Includes abdominal discomfort, abdominal pain, abdominal pain lower, abdominal pain upper, abdominal tenderness. d Includes multiple related adverse event terms, such as injection site bruising, injection site erythema, injection site pruritus, injection site pain, injection site rash, injection site reaction. e Includes asthenia, fatigue, lethargy, malaise. f Includes blood pressure decreased, hypotension, orthostatic hypotension. Adverse Reaction Placebo (N=958) % ZEPBOUND 5 mg (N=630) % ZEPBOUND 10 mg (N=948) % ZEPBOUND 15 mg (N=941) % Nausea 8 25 29 28 Diarrhea a 8 19 21 23 Vomiting 2 8 11 13 Constipation b 5 17 14 11 Abdominal Pain c 5 9 9 10 Dyspepsia 4 9 9 10 Injection Site Reactions d 2 6 8 8 Fatigue e 3 5 6 7 Hypersensitivity Reactions 3 5 5 5 Eructation 1 4 5 5 Hair Loss 1 5 4 5 Gastroesophageal Reflux Disease 2 4 4 5 Flatulence 2 3 3 4 Abdominal Distension 2 3 3 4 Dizziness 2 4 5 4 Hypotension f 0 1 1 2 In a clinical trial for weight reduction that included an intensive lifestyle intervention lead-in period (Study 3), 287 patients were treated with ZEPBOUND for up to 72 weeks. In a randomized withdrawal trial (Study 4), 783 patients were treated with ZEPBOUND for up to 36 weeks, and 335 of these patients were treated for up to 88 weeks [see Clinical Studies ( 14.1 )] . In Study 3, 10% of ZEPBOUND-treated patients and 2% of placebo-treated patients discontinued drug due to adverse reactions. In Study 4, 7% of patients discontinued ZEPBOUND treatment before randomized withdrawal at Week 36 due to adverse reactions. In Study 3 and Study 4, adverse reactions were similar to those reported in the two pooled ZEPBOUND clinical trials (Study 1 and Study 2). Gastrointestinal Adverse Reactions In a pool of Study 1 and 2, gastrointestinal adverse reactions occurred more frequently among patients receiving ZEPBOUND (5 mg 56%, 10 mg 56%, 15 mg 56%) than placebo (30%). More patients receiving ZEPBOUND 5 mg (1.9%), ZEPBOUND 10 mg (3.3%), and ZEPBOUND 15 mg (4.3%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.5%). The majority of nausea, vomiting, and/or diarrhea events occurred during dose escalation and decreased over time. Acute Pancreatitis In clinical trials of tirzepatide for a different indication, 14 events of acute pancreatitis were confirmed by adjudication in 13 tirzepatide-treated patients (0.23 patients per 100 years of exposure) versus 3 events in 3 comparator-treated patients (0.11 patients per 100 years of exposure). In a pool of two ZEPBOUND clinical trials for weight reduction (Studies 1 and 2), 0.2% of ZEPBOUND-treated patients had acute pancreatitis confirmed by adjudication (0.14 patients per 100 years of exposure) versus 0.2% of placebo-treated patients (0.15 patients per 100 years of exposure). The exposure-adjusted incidence rate for treatment-emergent adjudication-confirmed pancreatitis in the pooled clinical studies for OSA (Studies 5 and 6) was 0.84 patients per 100 years for ZEPBOUND and 0 for placebo-treated patients. Hypotension In a pool of Study 1 and 2, hypotension occurred more frequently among patients taking ZEPBOUND (1.6%) than patients taking placebo (0.1%). Hypotension was more frequently seen in ZEPBOUND-treated patients on concomitant antihypertensive therapy (2.2%) compared to ZEPBOUND-treated patients not on antihypertensive therapy (1.2%). Hypotension also occurred in association with gastrointestinal adverse events and dehydration. Hypersensitivity Reactions In a pool of Study 1 and 2, immediate hypersensitivity reactions (within one day after drug administration) occurred in 2.1% of ZEPBOUND-treated patients compared to 0.4% of placebo-treated patients, while non-immediate hypersensitivity reactions occurred in 3.5% of ZEPBOUND-treated patients compared to 2.7% of placebo-treated patients. Among ZEPBOUND-treated patients, hypersensitivity reactions were more frequent in those with anti-tirzepatide antibodies (6.2%) compared to those who did not develop anti-tirzepatide antibodies (3%) [see Clinical Pharmacology ( 12.6 )] . The majority of the hypersensitivity reactions in trials were skin reactions (e.g., rash, itching). Injection Site Reactions In ZEPBOUND-treated patients in a pool of Study 1 and 2, injection site reactions were more frequent in those with anti-tirzepatide antibodies (11.3%) compared to those who did not develop anti-tirzepatide antibodies (1%) [see Clinical Pharmacology ( 12.6 )] . Hair Loss Hair loss adverse reactions in ZEPBOUND-treated patients were associated with weight reduction. In a pool of Study 1 and 2, hair loss was reported more frequently in female than male patients in the ZEPBOUND (7.1% female versus 0.5% male) and placebo (1.3% female versus 0% male) treatment groups. No ZEPBOUND-treated patients and one placebo-treated patient discontinued study treatment due to hair loss. Other Adverse Reactions Acute Kidney Injury In a pool of Study 1 and 2, acute kidney injury was reported in 0.5% of ZEPBOUND-treated patients compared to 0.2% of placebo-treated patients. Acute Gallbladder Disease In a pool of Study 1 and 2, cholelithiasis was reported in 1.1% of ZEPBOUND-treated patients and 1% of placebo-treated patients, cholecystitis was reported in 0.7% of ZEPBOUND-treated patients and 0.2% of placebo-treated patients, and cholecystectomy was reported in 0.2% of ZEPBOUND-treated patients and no placebo-treated patients. Hypoglycemia In Study 2, a trial of patients with type 2 diabetes mellitus and BMI ≥27 kg/m 2 , hypoglycemia (plasma glucose <54 mg/dL) was reported in 4.2% of ZEPBOUND-treated patients versus 1.3% of placebo-treated patients. In Study 1, a trial of ZEPBOUND in adults with obesity/overweight without type 2 diabetes mellitus, there was no systematic capturing of hypoglycemia, but plasma glucose <54 mg/dL was reported in 0.3% of ZEPBOUND-treated patients versus no placebo-treated patients. Heart Rate Increase In a pool of Study 1 and 2, treatment with ZEPBOUND resulted in a mean increase in heart rate of 1 to 3 beats per minute compared to no increase in placebo-treated patients. Dysesthesia In a pool of Study 1 and 2, dysesthesia occurred more frequently among patients receiving ZEPBOUND (5 mg 0.2%, 10 mg 0.2%, 15 mg 0.4%) than placebo (0.1%). Dysgeusia In a pool of Study 1 and 2, dysgeusia was reported by 0.4% of ZEPBOUND-treated patients and no placebo-treated patients. Dry Mouth In a pool of Study 1 and 2, dry mouth or dry throat was reported by 1% of ZEPBOUND-treated patients and 0.1% of placebo-treated patients. Laboratory Abnormalities Amylase and Lipase Increase In a pool of Study 1 and 2, treatment with ZEPBOUND resulted in mean increases from baseline in serum pancreatic amylase concentrations of 20% to 25% and serum lipase concentrations of 28% to 35%, compared to mean increases from baseline in pancreatic amylase of 2.1% and serum lipase of 5.8% in placebo-treated patients. The clinical significance of elevations in amylase or lipase with ZEPBOUND is unknown in the absence of other signs and symptoms of pancreatitis. Adverse Reactions in Patients with Obstructive Sleep Apnea ZEPBOUND was evaluated in 2 randomized, double-blind, placebo-controlled trials (Study 5 and Study 6) that included a total of 467 adult patients with moderate to severe OSA and obesity [see Clinical Studies ( 14.2 )] . Study 5 enrolled 234 patients who were unable or unwilling to use Positive Airway Pressure (PAP) therapy and Study 6 enrolled 235 patients who were on PAP therapy. The adverse reactions observed with ZEPBOUND 10 mg or 15 mg administered subcutaneously once weekly were similar to those reported in the two pooled placebo controlled clinical trials for weight reduction (Study 1 and Study 2). 6.2 Postmarketing Experience The following adverse reactions have been reported during post-approval use of tirzepatide, the active ingredient in ZEPBOUND. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or to establish a causal relationship to drug exposure. Gastrointestinal: acute pancreatitis, hemorrhagic and necrotizing pancreatitis sometimes resulting in death, ileus, intestinal obstruction, severe constipation including fecal impaction Hypersensitivity: anaphylaxis, angioedema Pulmonary: Pulmonary aspiration has occurred in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation. Renal: acute renal failure or worsening of chronic renal failure, sometimes requiring hemodialysis

Clinical studies

14 CLINICAL STUDIES 14.1 Weight Reduction and Long-Term Maintenance Studies in Adults with Obesity or Overweight Weight Reduction in Adults with Obesity or Overweight, with or without Type 2 Diabetes Mellitus (Study 1 and Study 2) Overview of Study 1 and Study 2 The efficacy of ZEPBOUND for weight reduction in conjunction with a reduced-calorie diet and increased physical activity was studied in two randomized, double-blind, placebo-controlled fixed-dosage trials (Study 1 and Study 2) in adults aged 18 years and older. In Studies 1 and 2, all patients received a standard lifestyle intervention which included instruction on a reduced-calorie diet (approximately 500 kcal/day deficit) and increased physical activity counseling (recommended minimum of 150 min/week) that began with the first dose of study medication or placebo and continued throughout the trial. Patients also received counseling on behavior modification strategies to adhere to diet and exercise recommendations. In both trials, weight reduction was assessed after 72 weeks of treatment (at least 52 weeks at maintenance dose). Study 1 (NCT04184622) was a 72-week trial that enrolled 2,539 adult patients with obesity (BMI ≥30 kg/m 2 ), or with overweight (BMI 27 to <30 kg/m 2 ) and at least one weight-related comorbid condition, such as dyslipidemia, hypertension, obstructive sleep apnea, or CV disease; patients with type 2 diabetes mellitus were excluded. Patients were randomized in a 1:1:1:1 ratio to once weekly fixed dosage of ZEPBOUND 5 mg, ZEPBOUND 10 mg, ZEPBOUND 15 mg, or placebo, with an escalation period of up to 20 weeks followed by the maintenance period. At baseline, mean age was 45 years (range 18-84 years), 68% were female, 71% were White, 11% were Asian, 9% were American Indian/Alaska Native, and 8% were Black or African American. A total of 48% were Hispanic or Latino ethnicity. Mean baseline body weight was 104.8 kg and mean BMI was 38 kg/m 2 . Baseline characteristics included 32% with hypertension, 30% with dyslipidemia, 8% with obstructive sleep apnea, and 3% with CV disease. Study 2 (NCT04657003) was a 72-week trial that enrolled 938 adult patients with BMI ≥27 kg/m 2 and type 2 diabetes mellitus. Patients included in the trial had HbA1c 7-10% and were treated with either diet and exercise alone, or any oral anti-hyperglycemic agent except dipeptidyl peptidase-4 (DPP-4) inhibitors or GLP-1 receptor agonists. Patients who were taking insulin or injectable GLP-1 receptor agonists for type 2 diabetes mellitus were excluded. Patients were randomized in a 1:1:1 ratio to once weekly fixed dosage of ZEPBOUND 10 mg, ZEPBOUND 15 mg, or placebo with an escalation period of up to 20 weeks followed by the maintenance period. At baseline, mean age was 54 years (range 18-85 years), 51% were female, 76% were White, 13% were Asian, and 8% were Black or African American. A total of 60% were Hispanic or Latino ethnicity. Mean baseline body weight was 100.7 kg and mean BMI was 36.1 kg/m 2 . Baseline characteristics included 66% with hypertension, 61% with dyslipidemia, 8% with obstructive sleep apnea, and 10% with CV disease. Results for Study 1 and Study 2 The proportions of patients who discontinued study drug in Study 1 were 14.3%, 16.4%, and 15.1% for the 5 mg, 10 mg, and 15 mg ZEPBOUND-treated groups, respectively, and 26.4% for the placebo-treated group. The proportions of patients who discontinued study drug in Study 2 were 9.3% and 13.8% for the 10 mg and 15 mg ZEPBOUND-treated groups, respectively, and 14.9% for the placebo-treated group. For Studies 1 and 2, weight reduction was assessed after 72 weeks of treatment (at least 52 weeks at maintenance dose). In both studies, the primary efficacy parameters were mean percent change in body weight and the percentage of patients achieving ≥5% weight reduction from baseline to Week 72 (see Table 2 ). After 72 weeks of treatment, ZEPBOUND resulted in a statistically significant reduction in body weight compared with placebo, and greater proportions of patients treated with ZEPBOUND 5 mg, 10 mg, and 15 mg achieved at least 5% weight reduction compared to placebo. Among patients treated with ZEPBOUND 10 mg and 15 mg, greater proportions of patients achieved at least 10%, 15%, and 20% weight reduction compared to placebo (see Table 2 ). A reduction in body weight was observed with ZEPBOUND irrespective of age, sex, race, ethnicity, baseline BMI, and glycemic status. Table 2: Changes in Body Weight at Week 72 in Studies 1 and 2 in Patients with Obesity or Overweight Abbreviations: ANCOVA = analysis of covariance; CI = confidence interval; N = number of patients randomly assigned to study drug. a The intention-to-treat population includes all randomly assigned patients. For Study 1 at Week 72, body weight was missing for 21.6%, 10.2%, 10.5%, and 9.4% of patients randomly assigned to placebo, ZEPBOUND 5 mg, 10 mg, and 15 mg, respectively. For Study 2 at Week 72, body weight was missing for 11.1%, 4.8%, and 8.4% of patients randomly assigned to placebo, ZEPBOUND 10 mg, and 15 mg, respectively. The missing values were imputed by a hybrid approach using retrieved dropouts from the same treatment group (if missing not due to COVID-19) or using all non-missing data assuming missing at random (for missing solely due to COVID-19). b Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors. c Analyzed using logistic regression adjusted for baseline value. d p-value<0.001 (unadjusted 2-sided) for superiority, controlled for type I error rate. e Not controlled for type I error rate. Study 1 Study 2 Intention-to-Treat (ITT) Population a Placebo N = 643 ZEPBOUND 5 mg N = 630 ZEPBOUND 10 mg N = 636 ZEPBOUND 15 mg N = 630 Placebo N = 315 ZEPBOUND 10 mg N = 312 ZEPBOUND 15 mg N = 311 Body Weight Baseline mean (kg) 104.8 102.9 105.8 105.6 101.7 100.9 99.6 % Change from baseline b -3.1 -15.0 -19.5 -20.9 -3.2 -12.8 -14.7 % Difference from placebo b (95% CI) -11.9 (-13.4, -10.4) d -16.4 (-17.9, -14.8) d -17.8 (-19.3, -16.3) d -9.6 (-11.1, -8.1) d -11.6 (-13.0, -10.1) d % of Patients losing ≥5% body weight 34.5 85.1 88.9 90.9 32.5 79.2 82.8 % Difference from placebo (95% CI) 50.3 (44.3, 56.2) c,d 54.6 (49.1, 60.0) c,d 56.4 (50.9, 62.0) c,d 46.8 (39.5, 54.1) c,d 50.4 (43.1, 57.8) c,d % of Patients losing ≥10% body weight 18.8 68.5 78.1 83.5 9.5 60.5 64.8 % Difference from placebo (95% CI) 49.3 (43.6, 54.9) c,e 59.5 (54.2, 64.9) c,d 64.8 (59.6, 70.1) c,d 51.0 (44.4, 57.7) c,d 55.3 (48.6, 62.0) c,d % of Patients losing ≥15% body weight 8.8 48.0 66.6 70.6 2.7 39.7 48.0 % Difference from placebo (95% CI) 38.7 (33.6, 43.7) c,e 58.1 (53.2, 63.0) c,d 62.0 (57.2, 66.8) c,d 37.0 (31.1, 42.9) c,d 45.4 (39.4, 51.4) c,d % of Patients losing ≥20% body weight 3.1 30.0 50.1 56.7 1.0 21.5 30.8 % Difference from placebo (95% CI) 26.6 (22.4, 30.7) c,e 47.3 (42.7, 51.9) c,d 53.8 (49.3, 58.3) c,d 20.5 (15.7, 25.4) c,d 29.7 (24.3, 35.0) c,d The cumulative frequency distributions of change in body weight are shown in Figure 1 for Study 1 and Figure 2 for Study 2. One way to interpret this figure is to select a change in body weight of interest on the horizontal axis and note the corresponding proportions of patients (vertical axis) in each treatment group who achieved at least that degree of weight reduction. For example, note that the vertical line arising from -10% in Figure 1 intersects the ZEPBOUND 15 mg and placebo curves at approximately 83.5%, and 18.8%, respectively, which correspond to the values shown in Table 2 . Figure 1: Changes in Body Weight (%) from Baseline to Week 72 in Study 1 in Patients with Obesity or Overweight (without Type 2 Diabetes) Note: Based on average percent weight change of each randomized patient within each specific treatment arm from 100 imputed datasets including observed data and imputed data using hybrid approach for missing values. Figure 2: Changes in Body Weight (%) from Baseline to Week 72 in Study 2 in Patients with Obesity or Overweight and Type 2 Diabetes Note: Based on average percent weight change of each randomized patient within each specific treatment arm from 100 imputed datasets including observed data and imputed data using hybrid approach for missing values. The time courses of weight reduction with ZEPBOUND and placebo from baseline through Week 72 are depicted in Figure 3 for Study 1 and Figure 4 for Study 2. Figure 3: Change from Baseline (%) in Body Weight in Study 1 in Patients with Obesity or Overweight (without Type 2 Diabetes) Note: Displayed results are from the Intent-to-Treat Population. (1) Observed mean value from Week 0 to Week 72, and (2) least-squares mean ± standard error at Week 72 hybrid imputation (HI). Figure 4: Change from Baseline (%) in Body Weight in Study 2 in Patients with Obesity or Overweight and Type 2 Diabetes Note: Displayed results are from the Intent-to-Treat Population. (1) Observed mean value from Week 0 to Week 72, and (2) least squares mean ± standard error at Week 72 hybrid imputation (HI). Changes in waist circumference and cardiometabolic parameters with ZEPBOUND are shown in Table 3 for Study 1 and Study 2. Table 3: Changes in Anthropometry and Cardiometabolic Parameters at Week 72 in Studies 1 and 2 in Patients with Obesity or Overweight Abbreviations: ANCOVA = analysis of covariance; CI = confidence interval; N = number of patients randomly assigned to study drug. a The intention-to-treat population includes all randomly assigned patients. The missing values were imputed by a hybrid approach using retrieved dropouts from the same treatment group (if missing not due to COVID-19) or using all non-missing data assuming missing at random (for missing solely due to COVID-19). b Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors. c Analyzed using log-transformed data. d p-value<0.001 (unadjusted 2-sided) for superiority, controlled for type I error rate. e Not controlled for type I error rate. f Least-squares mean from mixed model for repeated measures adjusted for baseline value and other stratification factors. g Baseline value is the geometric mean. Study 1 Study 2 Intention-to-Treat (ITT) Population a Placebo N = 643 ZEPBOUND 5 mg N = 630 ZEPBOUND 10 mg N = 636 ZEPBOUND 15 mg N = 630 Placebo N = 315 ZEPBOUND 10 mg N = 312 ZEPBOUND 15 mg N = 311 Waist Circumference (cm) Baseline mean 114.0 113.2 114.8 114.4 116.0 114.2 114.6 Change from baseline b -4.0 -14.0 -17.7 -18.5 -3.3 -10.8 -13.1 Difference from placebo b (95% CI) -10.1 (-11.6, -8.6) e -13.8 (-15.2, -12.3) d -14.5 (-15.9, -13.0) d -7.4 (-9.0, -5.9) d -9.8 (-11.2, -8.3) d Systolic Blood Pressure (mmHg) Baseline mean 122.9 123.6 123.8 123.0 131.0 130.6 130.0 Change from baseline b -1.0 -6.6 -7.7 -7.4 -1.2 -5.6 -7.1 Difference from placebo b (95% CI) -5.6 (-7.2, -3.9) e -6.7 (-8.4, -5.0) e -6.4 (-8.0, -4.8) e -4.4 (-6.7, -2.1) e -5.9 (-8.3, -3.6) e Diastolic Blood Pressure (mmHg) Baseline mean 79.6 79.3 79.9 79.3 79.4 80.2 79.7 Change from baseline b -0.8 -4.9 -5.0 -4.5 -0.3 -2.1 -2.9 Difference from placebo b (95% CI) -4.1 (-5.2, -3.0) e -4.2 (-5.3, -3.0) e -3.7 (-4.8, -2.7) e -1.8 (-3.3, -0.4) e -2.7 (-4.2, -1.2) e Pulse Rate (beats per minute) Baseline mean 72.9 72.4 71.8 72.4 74.8 75.9 75.6 Change from baseline f 0.1 0.6 2.3 2.6 -0.5 0.6 1.0 Difference from placebo f (95% CI) 0.5 (-0.5, 1.5) e 2.2 (1.2, 3.2) e 2.5 (1.5, 3.4) e 1.2 (-0.1, 2.5) e 1.5 (0.2, 2.8) e Total Cholesterol (mg/dL) Baseline mean g 187.5 187.1 190.6 187.5 174.9 173.9 167.0 % change from baseline b -1.8 -3.8 -4.4 -6.3 2.8 -2.8 -1.0 Relative difference from placebo b (95% CI) -2.1 (-4.5, 0.4) c,e -2.7 (-5.1, -0.2) c,e -4.6 (-6.8, -2.2) c,e -5.5 (-8.7, -2.2) c,e -3.8 (-7.1, -0.3) c,e LDL Cholesterol (mg/dL) Baseline mean g 109.4 108.7 112.3 109.3 92.4 90.5 85.7 % change from baseline b -1.7 -4.6 -5.6 -7.1 7.4 1.8 4.1 Relative difference from placebo b (95% CI) -2.9 (-6.6, 0.9) c,e -4.0 (-7.5, -0.5) c,e -5.5 (-8.9, -2.0) c,e -5.2 (-10.1, 0.1) c,e -3.0 (-8.4, 2.6) c,e HDL Cholesterol (mg/dL) Baseline mean g 46.6 47.6 47.6 47.6 42.7 43.8 42.2 % change from baseline b -0.7 6.9 9.2 8.0 0.2 8.2 9.7 Relative difference from placebo b (95% CI) 7.7 (4.6, 10.8) c,e 9.9 (6.7, 13.2) c,e 8.7 (5.7, 11.8) c,e 8.0 (4.2, 11.8) c,e 9.5 (5.6, 13.5) c,e Non-HDL Cholesterol (mg/dL) Baseline mean g 138.3 137.0 140.4 137.5 129.6 127.2 121.9 % change from baseline b -2.3 -8.0 -9.4 -11.7 3.7 -6.6 -5.2 Relative difference from placebo b (95% CI) -5.8 (-8.9, -2.6) c,e -7.2 (-10.3, -4.1) c,e -9.6 (-12.4, -6.6) c,e -9.9 (-14.1, -5.6) c,e -8.5 (-12.9, -4.0) c,e Triglycerides (mg/dL) Baseline mean g 130.8 128.7 125.7 128.1 165.0 158.8 158.5 % change from baseline b -5.6 -21.2 -23.8 -29.1 -3.3 -27.1 -27.3 Relative difference from placebo b (95% CI) -16.5 (-21.2, -11.4) c,e -19.3 (-23.9, -14.4) c,e -24.9 (-29.1, -20.4) c,e -24.6 (-30.0, -18.7) c,e -24.8 (-30.3, -18.9) c,e HbA1c (%) Baseline mean 5.6 5.6 5.5 5.6 8.0 8.0 8.1 Change from baseline b -0.1 -0.4 -0.4 -0.4 -0.5 -2.1 -2.1 Difference from placebo b (95% CI) -0.3 (-0.3, -0.2) e -0.4 (-0.4, -0.3) e -0.4 (-0.4, -0.3) e -1.6 (-1.7, -1.4) d -1.6 (-1.8, -1.4) d Figure 1 Figure 2 Figure 3 Figure 4 Weight Reduction Following Intensive Lifestyle Intervention in Adults with Obesity or Overweight (Study 3) Overview of Study 3 Study 3 (NCT04657016) was an 84-week trial with a 12-week intensive lifestyle intervention lead-in period (Week -12 to Week 0), followed by a 72-week randomized treatment period of ZEPBOUND versus placebo (Week 0 to Week 72) with a standard lifestyle intervention. Only patients who lost ≥5% body weight during the 12-week intensive lifestyle lead-in period entered the 72-week randomized treatment period. The trial initially enrolled 806 adult patients (aged 18 years and older) with obesity (BMI ≥30 kg/m 2 ), or with overweight (BMI 27 to <30 kg/m 2 ) and at least one weight-related comorbid condition, such as dyslipidemia, hypertension, obstructive sleep apnea, or CV disease; patients with type 2 diabetes mellitus were excluded. During the intensive lifestyle intervention lead-in period, lifestyle instruction was delivered 8 times over 12 weeks by a dietician or dietician-equivalent, with all patients receiving instruction to exercise for at least 150 minutes per week and to reduce their caloric intake to approximately 1,200 kcal/day (females) or 1,500 kcal/day (males). Patients also received counseling on behavior modification strategies to adhere to diet and exercise recommendations. At the end of the 12-week intensive lifestyle intervention lead-in period, 579 patients who achieved ≥5% weight reduction were randomized in a 1:1 ratio to ZEPBOUND or placebo for 72 weeks. ZEPBOUND dosages were escalated over a period of up to 20 weeks to a maximum tolerated dosage (MTD) of 10 mg or 15 mg subcutaneous once weekly. During the randomized treatment period, patients received a standard lifestyle instruction every 12 weeks on reduced-calorie diet (approximately 500 kcal/day deficit) and increased physical activity (recommended minimum of 150 min/week) that began with the first dose of ZEPBOUND or placebo and continued throughout the 72-week treatment period; behavior modification strategies were recommended as needed. Weight reduction was assessed after 72 weeks of treatment (at least 52 weeks at maintenance dose). For the 579 patients who were randomized, mean body weight at enrollment prior to entering the 12-week lifestyle lead-in period (Week -12) was 109.5 kg and mean BMI was 38.6 kg/m 2 . At randomization (Week 0), after the 12-week intensive lifestyle lead-in period, mean body weight was 101.9 kg and mean BMI was 35.9 kg/m 2 . The mean age of patients randomized to treatment was 46 years (range 18-77 years), 63% were female, 86% were White, 11% were Black or African American, and 1% were Asian. A total of 54% were Hispanic or Latino ethnicity. Baseline characteristics for the 579 randomized patients included 34% with hypertension, 26% with dyslipidemia, 10% with obstructive sleep apnea, and 2% with CV disease. Results for Study 3 At the end of the 12-week intensive lifestyle intervention lead-in, for patients who subsequently entered the randomized treatment period (n=579), the average body weight loss due to lifestyle was 6.9% (Week -12 to Week 0). Eighty-six percent (86%) of ZEPBOUND-treated patients had a maximum tolerated dosage of 15 mg weekly based on their final dose during the double-blind treatment period. The time course of weight reduction during the lead-in and from Week 0 to Week 72 with ZEPBOUND and placebo are depicted in Figure 5 . Figure 5: Change in Body Weight (%) After 12-Week Intensive Lifestyle Intervention Lead-In Followed by Randomized Treatment and a Standard Lifestyle Intervention (Study 3) in Patients with Obesity or Overweight Note: Displayed results are from the randomized Population. (1) Observed mean value from Week -12 to Week 72, and (2) least squares mean ± standard error at Week 72 hybrid imputation (HI). Change from Week -12 is not a primary endpoint in Study 3. The proportions of patients who discontinued study drug after randomization were 21.3% for the ZEPBOUND-treated group and 30.5% for the placebo-treated group. For Study 3, the primary efficacy parameters were mean percent change in body weight from randomization (Week 0) to Week 72 and the percentage of patients achieving ≥5% weight reduction from randomization (Week 0) to Week 72. Amongst randomized patients who already lost ≥5% body weight during the 12-week intensive lifestyle lead-in period, subsequent treatment with ZEPBOUND resulted in a statistically significant reduction in body weight compared to placebo from randomization (Week 0) to Week 72. A greater proportion of patients treated with ZEPBOUND achieved at least 5%, 10%, 15%, and 20% weight reduction from Week 0 to Week 72 compared to placebo (see Table 4 ). Table 4: Changes in Body Weight After 12-Week Intensive Lifestyle Intervention Lead-In Followed by Randomized Treatment and a Standard Lifestyle Intervention (Study 3) in Patients with Obesity or Overweight Abbreviations: ANCOVA = analysis of covariance; CI = confidence interval; MTD = maximum tolerated dose; N = number of patients randomly assigned to study drug. a The intent-to-treat population included only randomized patients with ≥5% weight loss at Week 0 after 12 weeks of intensive lifestyle intervention. During the 12-week lead-in period, 227 of 806 patients (28.2%) discontinued from the study. Of these 141 (17.5%) discontinued due to not achieving the randomization criteria of ≥5% weight reduction. b The intent-to-treat population includes all randomly assigned patients. For Study 3 at Week 72, body weight was missing for 23.6% and 8.7% of patients randomly assigned to placebo and ZEPBOUND MTD (10 or 15 mg). The missing values were imputed by a hybrid approach using retrieved dropouts from the same treatment group (if missing not due to COVID-19) or using all non-missing data assuming missing at random (for missing solely due to COVID-19). c Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors. d Analyzed using logistic regression adjusted for baseline value. e p-value<0.001 (unadjusted 2-sided) for superiority, controlled for type I error rate. Study 3 N = 579 a Body Weight Mean (kg) at Week -12 109.5 Intention-to-Treat (ITT) Population a,b Placebo N = 292 ZEPBOUND MTD (10 mg or 15 mg) N = 287 Body Weight Mean (kg) at Week 0 101.3 102.5 % Change from randomization at Week 72 c 2.5 -18.4 % Difference from placebo, at Week 72 c (95% CI) -20.8 (-23.2, -18.5) e % of Patients losing ≥5% body weight 16.5 87.5 % Difference from placebo (95% CI) 71.1 (63.6, 78.5) d,e % of Patients losing ≥10% body weight 8.9 76.7 % Difference from placebo (95% CI) 67.9 (60.7, 75.1) d,e % of Patients losing ≥15% body weight 4.2 65.4 % Difference from placebo (95% CI) 61.3 (54.5, 68.1) d,e % of Patients losing ≥20% body weight 2.2 44.7 % Difference from placebo (95% CI) 42.6 (36.0, 49.1) d,e Changes in waist circumference and cardiometabolic parameters are shown in Table 5 . Table 5: Changes in Anthropometry and Cardiometabolic Parameters After 12-Week Intensive Lifestyle Intervention Lead-In Followed by Randomized Treatment and a Standard Lifestyle Intervention (Study 3) in Patients with Obesity or Overweight Abbreviations: ANCOVA = analysis of covariance; CI = confidence interval; N = number of patients randomly assigned to study drug. a The intent-to-treat population included all randomly assigned patients. The missing values were imputed by a hybrid approach using retrieved dropouts from the same treatment group (if missing not due to COVID-19) or using all non-missing data assuming missing at random (for missing solely due to COVID-19). b Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors. c Analyzed using log-transformed data. d p-value<0.001 (unadjusted 2-sided) for superiority, controlled for type I error rate. e Not controlled for type I error rate. f Least-squares mean from mixed model for repeated measures adjusted for baseline value and other stratification factors. g Baseline and randomization values are the geometric mean. h Observed means are shown for change from Week -12 to Week 0. Least-square means are shown for change from Week 0 to Week 72. Intention-to-Treat (ITT) Population a All Randomized Patients N=579 Placebo N=292 ZEPBOUND MTD (10 mg or 15 mg) N=287 Baseline (Week - 12) Change from Week - 12 to Week 0 Randomization (Week 0) Change from Week 0 to Week 72 Randomization (Week 0) Change from Week 0 to Week 72 Difference from placebo, Week 0 to Week 72 (95% CI) Waist circumference (cm) h 116.1 -6.7 109.6 0.2 b 109.3 -14.6 b -14.8 b (-17.2, -12.5) d Systolic Blood Pressure (mmHg) h 126.2 -5.0 120.8 3.5 b 121.7 -5.1 b -8.6 b (-11.3, -6.0) e Diastolic Blood Pressure (mmHg) h 81.7 -2.9 78.3 2.1 b 79.3 -3.2 b -5.3 b (-6.9, -3.7) e Pulse Rate (beats per minute) h 73.0 -1.6 70.7 0.9 f 72.2 2.7 f 1.8 f (0.3, 3.4) e HbA1c (%) h 5.5 -0.1 5.4 0.0 b 5.3 -0.4 b -0.4 b (-0.5, -0.3) e Total Cholesterol (mg/dL) g,h 190.2 -8.6 181.6 4.3 181.7 -2.4 -6.4 b (-9.0, -3.6) c,e LDL Cholesterol (mg/dL) g,h 111.6 -3.5 107.5 4.4 108.0 -5.6 -9.6 b (-13.7, -5.4) c,e HDL Cholesterol (mg/dL) g,h 48.4 -1.2 47.8 5.4 46.9 15.2 9.3 b (4.5, 14.2) c,e Non-HDL Cholesterol (mg/dL) g,h 139.2 -7.4 131.5 4.4 132.4 -8.8 -12.6 b (-15.9, -9.3) c,e Triglycerides (mg/dL) g,h 123.1 -19.8 108.8 2.1 111.7 -23.5 -25.1 b (-30.9, -18.9) c,e Figure 5 Weight Reduction Following Randomized Withdrawal in Adults with Obesity or Overweight (Study 4) Overview of Study 4 Study 4 (NCT04660643) was an 88-week randomized withdrawal trial in which all patients received open-label ZEPBOUND during a 36-week lead-in period, followed by randomization to either continue ZEPBOUND or switch to placebo for 52 weeks. The trial enrolled 783 adult patients (aged 18 years and older) with obesity (BMI ≥30 kg/m 2 ), or with overweight (BMI 27 to <30 kg/m 2 ) and at least one weight-related comorbid condition, such as dyslipidemia, hypertension, obstructive sleep apnea, or CV disease; patients with type 2 diabetes mellitus were excluded. All patients received a standard lifestyle intervention which included instruction on a reduced-calorie diet (approximately 500 kcal/day deficit) and increased physical activity counseling (recommended minimum of 150 min/week) that began with the first dose of ZEPBOUND, during the lead-in period, and continued throughout the trial. During the 36-week open-label ZEPBOUND lead-in period, ZEPBOUND dosages were escalated over a period of up to 20 weeks to an MTD of 10 mg or 15 mg subcutaneous once weekly. After the lead-in period, patients were randomized at Week 36 to continue ZEPBOUND or switch to placebo for 52 weeks. Of the 783 patients who started ZEPBOUND at Week 0, 14.4% discontinued treatment before randomization at Week 36, and adverse events were the most common reason for discontinuation (6.8%). At Week 36, a total of 670 patients were randomized in a 1:1 ratio to ZEPBOUND MTD or placebo for 52 weeks. For the 670 randomized patients, at study entry (Week 0) mean body weight was 107.3 kg and mean BMI was 38.4 kg/m 2 , and at randomization (Week 36, after the open-label ZEPBOUND lead-in period) mean body weight was 85.2 kg and mean BMI was 30.5 kg/m 2 . Among the randomized patients, the mean age was 49 years (range 19-81 years), 71% were female, 80% were White, 11% were Black or African American, and 7% were Asian. A total of 44% were Hispanic or Latino ethnicity. Baseline characteristics for the 670 randomized patients included 35% with hypertension, 32% with dyslipidemia, 12% with obstructive sleep apnea, and 6% with CV disease. Results for Study 4 At the end of the 36-week open-label ZEPBOUND lead-in period, of the 670 randomized patients, 93% were on ZEPBOUND MTD of 15 mg weekly and 7% were on MTD of 10 mg weekly. After open-label ZEPBOUND treatment, randomized patients (n=670) had an average body weight loss of 20.9% (Week 0 to Week 36). The time course of weight reduction from Week 0 through Week 88 is depicted in Figure 6 . Figure 6: Change in Body Weight (%) After 36-Week Open-Label Treatment Followed by Randomized Withdrawal (Study 4) in Patients with Obesity or Overweight Note: Displayed results are from the randomized population. (1) Displayed results are observed mean value from Week 0 to Week 88 and (2) least squares mean ± standard error at Week 88 hybrid imputation (HI). Change from Week 0 was not a primary endpoint in Study 4. The proportions of patients who discontinued study drug after randomization at Week 36 were 10.4% for the ZEPBOUND-treated group and 17.9% for the placebo-treated group. For Study 4, the primary efficacy parameter was mean percent change in body weight from randomization (Week 36) to Week 88. After weight loss with ZEPBOUND treatment during the open-label lead-in period (Week 0 to Week 36), continued treatment with ZEPBOUND from randomization (Week 36) to Week 88 resulted in a statistically significant reduction in body weight compared with placebo (see Table 6 ). Table 6: Changes in Body Weight After 36-Week Open-Label Treatment Followed by Randomized Withdrawal (Study 4) in Patients with Obesity or Overweight Abbreviations: ANCOVA = analysis of covariance; CI = confidence interval; MTD = maximum tolerated dose; N = number of patients randomly assigned to study drug. a The intent-to-treat population included all randomly assigned patients and did not include 113 patients who were enrolled but not randomized. At Week 88, body weight was missing for 13.7% and 7.5% of patients randomly assigned to placebo and ZEPBOUND MTD (10 or 15 mg), respectively. The missing values were imputed by a hybrid approach using retrieved dropouts from the same treatment group (if missing not due to COVID-19) or using all non-missing data assuming missing at random (for missing solely due to COVID-19). b Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors. c p-value<0.001 (unadjusted 2-sided) for superiority, controlled for type I error rate. Study 4 N=670 a Body Weight Mean at Week 0 (kg) 107.3 Intention-to-Treat (ITT) Population a Placebo N=335 ZEPBOUND (MTD 10 mg or 15 mg) N=335 Body Weight Mean at Week 36 (kg) 85.8 84.6 % change from Week 36 at Week 88 b 14.0 -5.5 % difference from placebo at Week 88 (95% CI) b -19.4 (-21.2, -17.7) c Changes in waist circumference and cardiometabolic parameters in Study 4 are shown in Table 7 . Table 7: Mean Changes in Anthropometry and Cardiometabolic Parameters After 36-Week Open-Label Treatment Followed by Randomized Withdrawal (Study 4) in Patients with Obesity or Overweight Abbreviations: ANCOVA = analysis of covariance; CI = confidence interval; N = number of patients randomly assigned to study drug. a The intent-to-treat population included all randomly assigned patients. The missing values were imputed by a hybrid approach using retrieved dropouts from the same treatment group (if missing not due to COVID-19) or using all non-missing data assuming missing at random (for missing solely due to COVID-19). b Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors. c Analyzed using log-transformed data. d p-value<0.001 (unadjusted 2-sided) for superiority, controlled for type I error rate. e Not controlled for type I error rate. f Least-squares mean from mixed model for repeated measures adjusted for baseline value and other stratification factors. g Baseline and randomization values are the geometric mean. h Observed means are shown for change from Week 0 to Week 36. Least-square means are shown for change from Week 36 to Week 88. Intention-to-Treat (ITT) Population a All Randomized Patients N=670 Placebo N=335 ZEPBOUND MTD (10 mg or 15 mg) N=335 Baseline (Week 0) Change from Week 0 to Week 36 Randomization (Week 36) Change from Week 36 to Week 88 Randomization (Week 36) Change from Week 36 to Week 88 Difference from placebo, Week 36 to Week 88 (95% CI) Waist circumference (cm) h 115.2 -17.8 98.2 7.8 b 96.8 -4.3 b -12.1 b (-13.5, -10.6) d Systolic Blood Pressure (mmHg) h 126.1 -11.2 114.8 8.2 b 115.0 2.0 b -6.2 b (-8.2, -4.3) e Diastolic Blood Pressure (mmHg) h 80.9 -5.1 76.2 3.2 b 75.4 -0.7 b -3.8 b (-5.2, -2.4) e Pulse Rate (beats per minute) h 72.5 5.0 77.8 -5.2 f 77.1 -2.1 f 3.1 f (1.9, 4.3) e HbA1c (%) h 5.5 -0.5 5.0 0.3 b 5.1 -0.0 b -0.3 b (-0.3, -0.2) e Total Cholesterol (mg/dL) g,h 188.3 -12.4 176.1 8.0 175.9 2.7 -4.9 b (-7.4, -2.4) c,e LDL Cholesterol (mg/dL) g,h 108.6 -1.9 107.6 3.2 105.9 -3.5 -6.5 b (-10.0, -2.9) c,e HDL Cholesterol (mg/dL) g,h 49.9 -2.7 47.3 14.8 47.7 18.7 3.4 b (0.2, 6.6) c,e Non-HDL Cholesterol (mg/dL) g,h 135.8 -9.8 126.3 5.1 126.0 -3.4 -8.1 b (-11.3, -4.8) c,e Triglycerides (mg/dL) g,h 121.4 -40.4 85.5 13.5 90.9 -4.8 -16.1 b (-21.7, -10.0) c,e Figure 6 14.2 Obstructive Sleep Apnea Studies in Adults with Obesity Overview of Study 5 and Study 6 The efficacy of ZEPBOUND for moderate to severe obstructive sleep apnea (OSA) (apnea-hypopnea index [AHI] ≥15) in patients with obesity (BMI ≥30 kg/m 2 ) was evaluated in a master protocol clinical trial (NCT05412004) that included two randomized, double-blind, placebo-controlled trials (Study 5 and Study 6) of 52 weeks duration. The two trials enrolled a total of 469 adult patients. In Studies 5 and 6, patients were randomized in a 1:1 ratio to receive ZEPBOUND or placebo for 52 weeks. ZEPBOUND dosages were escalated over a period of up to 20 weeks to maximum tolerated dosage (MTD) of 10 mg or 15 mg subcutaneous once weekly [see Dosage and Administration ( 2.1 , 2.2 )] . Patients with type 2 diabetes mellitus were excluded and all patients received instruction on a reduced-calorie diet and increased physical activity counseling throughout the study. Study 5 enrolled 234 adult patients with moderate to severe OSA and obesity who were unable or unwilling to use Positive Airway Pressure (PAP) therapy. Patients had a mean age of 48 years (range: 20 to 76 years), 67% were male, 66% were White, 20% were Asian, 8% were American Indian/Alaska Native, and 6% were Black or African American. A total of 42% were Hispanic or Latino ethnicity. Study 6 enrolled 235 adult patients with moderate to severe OSA and obesity who were on PAP therapy. Patients had a mean age of 52 years (range: 26 to 79 years), 72% were male, 73% were White, 14% were Asian, 8% were American Indian/Alaska Native, and 5% were Black or African American. A total of 32% were Hispanic or Latino ethnicity. Table 8 describes the baseline disease characteristics of patients in Studies 5 and 6. Table 8: Baseline Disease Characteristics of Patients with OSA and Obesity in Study 5 and Study 6 Abbreviations: AHI = Apnea-Hypopnea Index; BMI = body-mass index; ESS = Epworth Sleepiness Score; OSA = obstructive sleep apnea; SD = standard deviation. a Moderate OSA was defined as an AHI ≥15 – 30 events/hour on polysomnogram at baseline. b Severe OSA was defined as an AHI ≥30 events/hour on polysomnogram at baseline. Study 5 (N=234) Study 6 (N=235) Baseline AHI (events/hour), mean (SD) 51.5 (31) 49.5 (26.7) Moderate OSA, % a 35.2 30.9 Severe OSA, % b 63.1 68.2 ESS Total, mean (SD) 10.5 (5.2) 10 (4.6) Total Hypoxic Burden (% min/hour), mean (SD) 208.4 (189.1) 193 (174.6) BMI (kg/m 2 ), mean (SD) 39.1 (7) 38.7 (6) Pre-diabetes, % 65 56.6 Hypertension, % 75.6 77.4 Cardiac disorders, % 10.3 11.1 Dyslipidemia, % 80.8 83.8 Results for Study 5 and Study 6 The primary endpoint for Studies 5 and 6 was the change from baseline in the apnea-hypopnea index (AHI) at Week 52. Patients in Study 5 were unable or unwilling to use PAP therapy, and patients in Study 6 were on PAP therapy and instructed to suspend PAP for 7 days prior to assessment of the primary endpoint. The clinical studies for OSA did not evaluate the timing or appropriateness of PAP discontinuation in patients who were previously compliant with PAP therapy. In Studies 5 and 6, treatment with ZEPBOUND for 52 weeks resulted in a statistically significant reduction in AHI compared with placebo, and greater proportions of patients treated with ZEPBOUND achieved remission or mild non-symptomatic OSA compared to placebo. Table 9 provides the efficacy results for Studies 5 and 6. A reduction in AHI was observed with ZEPBOUND irrespective of age, sex, ethnicity, baseline BMI, or baseline OSA severity. In both Studies 5 and 6, patients treated with ZEPBOUND achieved a greater reduction in systolic blood pressure and high-sensitivity C-reactive protein levels compared to placebo. Table 9: Changes in Apnea-Hypopnea Index (AHI), Hypoxic Burden, and Body Weight at Week 52 in Study 5 and Study 6 Abbreviations: AHI = Apnea-Hypopnea Index; ANCOVA = analysis of covariance; CI = confidence interval; ESS = Epworth Sleepiness Scale; h = hour; MTD = maximum tolerated dose; N = number of participants randomly assigned and received at least 1 dose of study drug. a Analyses were based on the modified intent-to-treat population which was defined as randomly assigned participants who were exposed to at least 1 dose of study intervention; two participants in Study 6 were randomized but did not receive study drug. b Least-squares mean from ANCOVA adjusted for baseline values and stratification factors, with multiple imputation for missing data at Week 52. c Analyzed using log transformed data. d Calculated by combining proportion of participants achieving target in imputed datasets. e p-value <0.001 (unadjusted 2-sided) for superiority, controlled for multiplicity. f Baseline value is the geometric mean. Modified Intent-to-Treat (mITT) Population a Study 5 Study 6 Placebo N = 120 ZEPBOUND MTD (10 mg or 15 mg) N = 114 Placebo N = 114 ZEPBOUND MTD (10 mg or 15 mg) N = 119 AHI (events/hr) Baseline mean 50.1 52.9 53.1 46.1 Change from baseline b -5.3 -25.3 -5.5 -29.3 Difference from placebo b (95% CI) -20 (-25.8, -14.2) e -23.8 (-29.6, -17.9) e % change in AHI % change from baseline b -3 -50.7 -2.5 -58.7 % difference from placebo b (95% CI) -47.7 (-65.8, -29.6) e -56.2 (-73.7, -38.7) e % of patients with ≥50% reduction in AHI d 19 61.2 23.3 72.4 % difference from placebo (95% CI) 42.8 (30.8, 54.8) e 48.6 (36.6, 60.7) e Remission or mild non-symptomatic OSA % of Patients with AHI <5 or AHI 5-14 and ESS≤10 d 15.9 42.2 14.3 50.2 % difference from placebo (95% CI) 28.7 (18.3, 39.2) e 33.2 (22.1, 44.3) e Sleep apnea-specific hypoxic burden (% min/h) Baseline mean f 137.8 153.6 142.1 132.2 Change from baseline b -25.1 -95.2 -41.7 -103 Difference from placebo b (95% CI) -70.1 (-90.9, -49.3) c,e -61.3 (-84.7, -37.9) c,e Body weight (kg) Baseline mean 112.8 116.7 115.1 115.8 % change from baseline b -1.6 -17.7 -2.3 -19.6 % difference from placebo b (95% CI) -16.1 (-18, -14.2) e -17.3 (-19.3, -15.3) e The time course of change in AHI with ZEPBOUND and placebo from baseline through Week 52 are shown in Figure 7 for Study 5. Similar results were demonstrated for Study 6. Figure 7: Change from Baseline in Apnea-Hypopnea Index (AHI) Through Week 52 (Study 5) Abbreviations: AHI = Apnea-Hypopnea Index; ANCOVA = analysis of covariance; MI = multiple imputation; MTD = maximum tolerated dose. Note: Displayed results are from modified Intent-to-Treat Population. (1) Observed mean value from Week 0 through Week 52, and (2) least squares mean ± standard error at Week 52 from ANCOVA adjusted for baseline values and stratification factors, with multiple imputation of missing data. Figure 7 Sleep-Related Impairment In OSA clinical studies (Study 5 and Study 6), ZEPBOUND-treated patients showed improvement in sleep-related impairment compared to those who received placebo. Sleep-related impairment was assessed using the Patient-Reported Outcomes Measurement Information System ® (PROMIS) Short Form Sleep-Related Impairment 8a.

Other label records (6)

These may cover different packages or labelers. Older excerpts without full document identity are source links only.

  • MOUNJARO (dailymed.nlm.nih.gov)

    SUBCUTANEOUS · A-S Medication Solutions · label effective Jul 29, 2026

  • MOUNJARO (dailymed.nlm.nih.gov)

    SUBCUTANEOUS · A-S Medication Solutions · label effective Jul 29, 2026

  • MOUNJARO (dailymed.nlm.nih.gov)

    SUBCUTANEOUS · A-S Medication Solutions · label effective Jul 29, 2026

  • MOUNJARO (dailymed.nlm.nih.gov)

    SUBCUTANEOUS · A-S Medication Solutions · label effective Jul 29, 2026

  • MOUNJARO (dailymed.nlm.nih.gov)

    SUBCUTANEOUS · A-S Medication Solutions · label effective Jul 29, 2026

  • MOUNJARO (dailymed.nlm.nih.gov)

    SUBCUTANEOUS · A-S Medication Solutions · label effective Jul 29, 2026

Source: submitted product labeling via openFDA. A listing does not establish FDA approval and may differ from current approved labeling. Read the current prescribing information and consult a clinician.
Tolerability

Side effects reported in the trial

Reported adverse events and treatment discontinuation from the cited trial. These figures do not predict an individual response.

Discontinued for side effects

6.2% (nejm.org/doi/full/10.1056/NEJMoa2206038) (6.2% vs 2.6% placebo (15 mg) · SURMOUNT-1 (15 mg, 72 wks, obesity))

Reported as 6.2% vs 2.6% placebo (15 mg). The share of trial participants who stopped treatment because of adverse events. This does not measure all side effects or all reasons for stopping.

Had nausea

31% (nejm.org/doi/full/10.1056/NEJMoa2206038) (Nausea in the drug arm · SURMOUNT-1 (15 mg, 72 wks, obesity))

The share of participants who reported nausea in this trial. Severity and duration are not captured by this percentage.

Nausea (31%), diarrhea (23%), and vomiting (12%) were the most common events at 15 mg, generally mild-to-moderate and concentrated during dose escalation.

From SURMOUNT-1 (15 mg, 72 wks, obesity). Tolerability figures come from each drug's own trial (different doses, durations, and populations), so compare them as a guide, not a head-to-head. Source (nejm.org).

Safety signals

Beyond the US label

Regulators' safety notices beside the US label, each cited and dated. Where it matters, each says whether the label itself mentions it yet.

Before surgery: risk of pulmonary aspiration

In November 2024 the FDA added a class-wide warning to every GLP-1 label. Because these drugs slow stomach emptying, food can remain in the stomach before a procedure and be inhaled into the lungs (aspiration) during general anesthesia or deep sedation, even after normal fasting. Tell your care team you take a GLP-1 well before any planned surgery or sedation.

FDA (class-wide label update) (secure.medicalletter.org) · as of Nov 5, 2024

Eyes: FDA requires a warning about sudden vision loss (NAION)

On November 9, 2026 the FDA said it is "requiring application holders for all GLP-1 RA medications to add information to the Warnings and Precautions section of labeling about the potential increased risk of NAION" (non-arteritic anterior ischemic optic neuropathy), which it describes as "a rare condition that can result in acute, painless, decreased vision in one eye, including permanent vision loss." Its analysis of 126 randomized trials found 6.4 NAION cases per 100,000 person-years on a GLP-1, against 3.8 on placebo or another glucose-lowering medicine. Its list names every GLP-1 sold in the US, from Ozempic, Wegovy, Mounjaro and Zepbound to Foundayo. FDA's advice: "Patients should contact their health care professional right away if they have any of these symptoms." None of the current US labels of Byetta, Wegovy, Rybelsus/Ozempic tablets, Trulicity, Saxenda, Victoza, Mounjaro, Zepbound, Ozempic and Foundayo mentions NAION; every new revision is searched in full within a day of its publication.

FDA Drug Safety Communication, November 9, 2026 (fda.gov) · as of Nov 9, 2026

Mood: the FDA found no increased risk of suicidal thoughts

In January 2026 the FDA asked the makers of Wegovy, Saxenda and Zepbound to remove the warning about suicidal behavior and ideation from their labels, after a review of 91 placebo-controlled trials (107,910 patients) and a study of more than 2 million people's insurance claims found no increased risk. Wegovy's label shows the warning removed in February 2026. The FDA still advises telling your health care professional about new or worsening depression, suicidal thoughts, or any unusual changes in mood or behavior.

FDA Drug Safety Communication (fda.gov) · as of Jan 13, 2026

Around the world

Tirzepatide international price references

Published price snapshots, grouped by brand and country. Reporting years, doses, and price definitions differ, so these records cannot establish today’s price gap.

  • India · Mounjaro₹13,125-25,781/mo by dose (~$139-272), Nov 2026 (pharmeasy.in) (Maximum retail price per KwikPen (four weekly doses), 2.5 mg to 15 mg; selling prices can be lower. Lilly launched the KwikPen in India in August 2025 at ₹14,000 for the starting dose, before India's September 2025 tax cut.)
  • Japan · Mounjaro$319/mo (2023 list price) (healthsystemtracker.org) ($319/mo (2023 list price))
  • Netherlands · Mounjaro$444/mo (2023 list price) (healthsystemtracker.org) ($444/mo (2023 list price))
  • United Kingdom · Mounjaro£133.19-287.99/mo private by dose (~$180-389), Nov 2026 (medino.com) (Lowest private-pharmacy price per pen at each dose, 2.5 mg to 15 mg, across 28 UK providers checked Nov 2, 2026; NHS patients pay only the prescription charge.)
  • United States · Mounjaro~$1,112/mo (therxindex.com) (US WAC list price (28-day); raised from $1,069 on Jan 1, 2026. Zepbound's list is ~$1,086.)

References include manufacturer list prices and reported pharmacy prices, not a single comparable measure of patient cost. Each amount links to its original record, or names the shop it was read at. Confirm current local pricing and coverage with a licensed pharmacy.

Studied together

Direct trial comparisons

Read the results for the exact products, doses, and participants studied.

Evidence

Clinical trials

230 of 317 registered studies indexed. Showing up to 12 records: posted results first, then late-phase trials. Registry counts are not a measure of evidence quality.

  • Primary outcome: Number of Participants From Randomization to First Occurrence of Death From MACE-3 [Composite Endpoint of Major Adverse Cardiovascular Events Death From Cardiovascular Causes, Myocardial Infarction (MI) or Stroke]

    Selected primary outcome

    Results · Nov 17, 2026 UTC

    Number of Participants From Randomization to First Occurrence of Death From MACE-3 [Composite Endpoint of Major Adverse Cardiovascular Events Death From Cardiovascular Causes, Myocardial Infarction (MI) or Stroke]

    Number · participants · From randomization (week 0) up to week 259

    Analysis population: Modified Intention-to-treat (mITT) Population included all randomized participants who were grouped according to the treatment assigned at randomization.

    Tirzepatide (MTD)
    801 participants (clinicaltrials.gov/study/NCT04255433)

    Overall outcome: 6586 Participants (clinicaltrials.gov/study/NCT04255433) analyzed

    1.5 mg Dulaglutide
    862 participants (clinicaltrials.gov/study/NCT04255433)

    Overall outcome: 6579 Participants (clinicaltrials.gov/study/NCT04255433) analyzed

    Outcome definition & treatment groups

    Number of participants with first occurrence of Clinical Endpoint Committee (CEC), a composite endpoint i.e., from time of randomization to first occurrence of cardiovascular (CV) death, myocardial infarction and stroke combined data was reported. Time to event was defined as the number of days from the date of randomization to the first occurrence of any of these events during the study follow-up period. Participants without an event were censored at their last known contact or end of follow-up.

    Tirzepatide (MTD): Participants received a starting dose of 2.5 mg tirzepatide administered as SC injection QW and escalated by 2.5 mg every 4 weeks to a maximum of 15 mg QW or MTD tolerated by the participant (5 mg QW or 10 mg QW) for up to 5 years.

    1.5 mg Dulaglutide: Participants received 1.5 mg dulaglutide administered as SC injection QW for up to 5 years.

    One of 1 registered primary outcome, selected for its reported data and weight or blood-sugar endpoint where available. These are registry values; published analyses may differ. Full results on ClinicalTrials.gov (clinicaltrials.gov).

  • Primary outcome: Percent Change From Baseline in Body Weight (Primary Treatment Period)

    Selected primary outcome

    Results · Nov 17, 2026 UTC

    Percent Change From Baseline in Body Weight (Primary Treatment Period)

    Least-squares mean · percent change · Baseline, Week 72

    Analysis population: All participants who received at least one dose of study drug and had baseline and at least one post-baseline body weight value, excluding data after prematurely stopping study drug.

    Placebo
    -2.4 percent change (clinicaltrials.gov/study/NCT04184622)

    Standard Error: 0.40 (clinicaltrials.gov)

    Overall outcome: 635 Participants (clinicaltrials.gov/study/NCT04184622) analyzed

    5 mg Tirzepatide
    -16.0 percent change (clinicaltrials.gov/study/NCT04184622)

    Standard Error: 0.39 (clinicaltrials.gov)

    Overall outcome: 623 Participants (clinicaltrials.gov/study/NCT04184622) analyzed

    10 mg Tirzepatide
    -21.4 percent change (clinicaltrials.gov/study/NCT04184622)

    Standard Error: 0.39 (clinicaltrials.gov)

    Overall outcome: 629 Participants (clinicaltrials.gov/study/NCT04184622) analyzed

    15 mg Tirzepatide
    -22.5 percent change (clinicaltrials.gov/study/NCT04184622)

    Standard Error: 0.39 (clinicaltrials.gov)

    Overall outcome: 625 Participants (clinicaltrials.gov/study/NCT04184622) analyzed

    Outcome definition & treatment groups

    Least Squares (LS) Mean was calculated using mixed-model repeated measures (MMRM) with baseline, analysis country, sex, prediabetes status at randomization, treatment, time, treatment\*time (Type III sum of squares) in the model.

    Placebo: Primary Treatment Period (Week 0-Week 72): Participants with normoglycemia or prediabetes at the time of randomization received QW SC doses of a matching placebo, administered over a period of 72 weeks.

    5 mg Tirzepatide: Primary Treatment Period (Week 0-Week 72): Participants with normoglycemia or prediabetes at the time of randomization received QW SC doses of tirzepatide, starting at 2.5 mg and increasing by 2.5 mg every 4 weeks until reaching a dose of 5 mg, which was then maintained up to week 72.

    10 mg Tirzepatide: Primary Treatment Period (Week 0-Week 72): Participants with normoglycemia or prediabetes at the time of randomization received QW SC doses of tirzepatide, starting at 2.5 mg and increasing by 2.5 mg every 4 weeks until reaching a dose of 10 mg, which was then maintained up to week 72.

    15 mg Tirzepatide: Primary Treatment Period (Week 0-Week 72): Participants with normoglycemia or prediabetes at the time of randomization received QW SC doses of tirzepatide, starting at 2.5 mg and increasing by 2.5 mg every 4 weeks until reaching a dose of 15 mg, which was then maintained up to week 72.

    One of 2 registered primary outcomes, selected for its reported data and weight or blood-sugar endpoint where available. These are registry values; published analyses may differ. Full results on ClinicalTrials.gov (clinicaltrials.gov).

  • Primary outcome: Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)

    Selected primary outcome

    Results · Nov 17, 2026 UTC

    Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)

    Least-squares mean · Percentage of HbA1c · Baseline, Week 52

    Analysis population: All randomized participants who received at least one dose of study drug and had a baseline and at least 1 post-baseline value, excluding participants discontinuing study drug due to inadvertent enrollment

    10 mg Tirzepatide
    -2.43 Percentage of HbA1c (clinicaltrials.gov/study/NCT03730662)

    Standard Error: 0.053 (clinicaltrials.gov)

    Overall outcome: 289 Participants (clinicaltrials.gov/study/NCT03730662) analyzed

    15 mg Tirzepatide
    -2.58 Percentage of HbA1c (clinicaltrials.gov/study/NCT03730662)

    Standard Error: 0.053 (clinicaltrials.gov)

    Overall outcome: 291 Participants (clinicaltrials.gov/study/NCT03730662) analyzed

    Insulin Glargine
    -1.44 Percentage of HbA1c (clinicaltrials.gov/study/NCT03730662)

    Standard Error: 0.030 (clinicaltrials.gov)

    Overall outcome: 887 Participants (clinicaltrials.gov/study/NCT03730662) analyzed

    Outcome definition & treatment groups

    HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model for post-baseline measures: Variable = Baseline + Pooled Country + Baseline sodium-glucose co-transporter-2 inhibitor (SGLT-2i) use Flag (Yes, No) + Treatment + Time + Treatment\*Time (Type III sum of squares).

    10 mg Tirzepatide: 10 mg tirzepatide administered SC once a week.

    15 mg Tirzepatide: 15 mg tirzepatide administered SC once a week.

    Insulin Glargine: Insulin glargine administered SC once a day. Doses were individualized and titrated according to protocol-defined targets. The starting dose of insulin glargine was 10 IU/day at bedtime, titrated to a FBG \<100 mg/dL, following a treat-to-target (TTT) algorithm.

    One of 1 registered primary outcome, selected for its reported data and weight or blood-sugar endpoint where available. These are registry values; published analyses may differ. Full results on ClinicalTrials.gov (clinicaltrials.gov).

  • Primary outcome: Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)

    Selected primary outcome

    Results · Nov 6, 2026 UTC

    Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)

    Least-squares mean · Percentage of HbA1c · Baseline, Week 52

    Analysis population: All randomized participants who received at least one dose of study drug and had a baseline and at least 1 post-baseline value, excluding participants discontinuing study drug due to inadvertent enrollment and data after initiating rescue antihyperglycemic medication or stopping study drug (last dose date +7 days)

    10 mg Tirzepatide
    -2.20 Percentage of HbA1c (clinicaltrials.gov/study/NCT03882970)

    Standard Error: 0.051 (clinicaltrials.gov)

    Overall outcome: 291 Participants (clinicaltrials.gov/study/NCT03882970) analyzed

    15 mg Tirzepatide
    -2.37 Percentage of HbA1c (clinicaltrials.gov/study/NCT03882970)

    Standard Error: 0.050 (clinicaltrials.gov)

    Overall outcome: 294 Participants (clinicaltrials.gov/study/NCT03882970) analyzed

    Insulin Degludec
    -1.34 Percentage of HbA1c (clinicaltrials.gov/study/NCT03882970)

    Standard Error: 0.049 (clinicaltrials.gov)

    Overall outcome: 317 Participants (clinicaltrials.gov/study/NCT03882970) analyzed

    Outcome definition & treatment groups

    HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with covariates Baseline + Pooled Country + Baseline Oral Antihyperglycemic Medication (OAM) Use (Metformin (Met), Met plus SGLT-2i) + Treatment + Time + Treatment\*Time (Type III sum of squares).

    10 mg Tirzepatide: 10 mg tirzepatide administered SC once a week.

    15 mg Tirzepatide: 15 mg tirzepatide administered SC once a week SC.

    Insulin Degludec: Insulin degludec administered SC once a day. Doses were individualized and titrated according to protocol-defined targets. The starting dose of insulin degludec was 10 IU/day ideally at bedtime, titrated to a fasting blood glucose (FBG) \<90 milligram per Deciliter (mg/dL), following a treat-to-target (TTT) algorithm based on the last 3 FBG values.

    One of 1 registered primary outcome, selected for its reported data and weight or blood-sugar endpoint where available. These are registry values; published analyses may differ. Full results on ClinicalTrials.gov (clinicaltrials.gov).

  • Primary outcome: Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses of Tirzepatide 5 mg, 10 mg and 15 mg)

    Selected primary outcome

    Results · Nov 3, 2026 UTC

    Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses of Tirzepatide 5 mg, 10 mg and 15 mg)

    Least-squares mean · Percentage of HbA1c · Baseline, Week 52

    Analysis population: All randomly assigned participants who took at least 1 dose of study drug and had a baseline and at least 1 post-baseline value for this analysis, excluding participants discontinuing study drug due to inadvertent enrollment and data after initiating rescue antihyperglycemic medication or prematurely stopping study drug. This analysis was planned to measure the outcome for pooled 5 mg, 10 mg and 15 mg tirzepatide.

    Pooled 5 mg/10 mg/15 mg Tirzepatide
    -2.26 Percentage of HbA1c (clinicaltrials.gov/study/NCT04537923)

    Standard Error: 0.048 (clinicaltrials.gov)

    Overall outcome: 708 Participants (clinicaltrials.gov/study/NCT04537923) analyzed

    Insulin Lispro
    -1.16 Percentage of HbA1c (clinicaltrials.gov/study/NCT04537923)

    Standard Error: 0.049 (clinicaltrials.gov)

    Overall outcome: 692 Participants (clinicaltrials.gov/study/NCT04537923) analyzed

    Outcome definition & treatment groups

    HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with covariates Baseline + Pooled Country + Baseline Metformin Use (Yes, No) + Treatment + Time + Treatment\*Time (Type III sum of squares).

    Pooled 5 mg/10 mg/15 mg Tirzepatide: Participants received either 5 mg or 10 mg or 15 mg tirzepatide administered SC once a week.

    Insulin Lispro: Participants received Insulin lispro (U100) administered SC three times a day.

    One of 1 registered primary outcome, selected for its reported data and weight or blood-sugar endpoint where available. These are registry values; published analyses may differ. Full results on ClinicalTrials.gov (clinicaltrials.gov).

  • Primary outcome: Percent Change From Baseline in Body Weight

    Selected primary outcome

    Results · Nov 1, 2026 UTC

    Percent Change From Baseline in Body Weight

    Least-squares mean · percent change · Baseline, Week 72

    Analysis population: All randomized participants who received at least one dose of study drug. Only participants with non-missing baseline value and at least one non-missing post-baseline value of the response variable were included in analysis.

    Placebo
    -3.3 percent change (clinicaltrials.gov/study/NCT04657003)

    Standard Error: 0.49 (clinicaltrials.gov)

    Overall outcome: 311 Participants (clinicaltrials.gov/study/NCT04657003) analyzed

    10 mg Tirzepatide
    -13.4 percent change (clinicaltrials.gov/study/NCT04657003)

    Standard Error: 0.48 (clinicaltrials.gov)

    Overall outcome: 309 Participants (clinicaltrials.gov/study/NCT04657003) analyzed

    15 mg Tirzepatide
    -15.7 percent change (clinicaltrials.gov/study/NCT04657003)

    Standard Error: 0.49 (clinicaltrials.gov)

    Overall outcome: 309 Participants (clinicaltrials.gov/study/NCT04657003) analyzed

    Outcome definition & treatment groups

    Least Squares Mean (LSMean) calculated using Mixed Model Repeated Measures (MMRM) model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Type of Antihyperglycemic Medication (AHM) Used at Randomization + Treatment + Time + Treatment\*Time (Type III sum of squares).

    Placebo: Participants received Placebo administered SC QW.

    10 mg Tirzepatide: Participants received 10 mg Tirzepatide administered SC QW.

    15 mg Tirzepatide: Participants received 15 mg Tirzepatide administered SC QW.

    One of 2 registered primary outcomes, selected for its reported data and weight or blood-sugar endpoint where available. These are registry values; published analyses may differ. Full results on ClinicalTrials.gov (clinicaltrials.gov).

  • Primary outcome: Mean Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)

    Selected primary outcome

    Results · Nov 2, 2026 UTC

    Mean Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)

    Least-squares mean · Percentage of HbA1c · Baseline, Week 40

    Analysis population: All randomized participants belonging to the 10 mg, 15 mg Tirzepatide and Insulin Glargine arms who received at least one dose of study drug, had a baseline and at least one post-baseline value, excluding data after initiating rescue antihyperglycemic medication or stopping study drug (last dose date + 7 days).

    10 mg Tirzepatide
    -2.44 Percentage of HbA1c (clinicaltrials.gov/study/NCT04093752)

    Standard Error: 0.073 (clinicaltrials.gov)

    Overall outcome: 194 Participants (clinicaltrials.gov/study/NCT04093752) analyzed

    15 mg Tirzepatide
    -2.49 Percentage of HbA1c (clinicaltrials.gov/study/NCT04093752)

    Standard Error: 0.072 (clinicaltrials.gov)

    Overall outcome: 193 Participants (clinicaltrials.gov/study/NCT04093752) analyzed

    Insulin Glargine
    -0.95 Percentage of HbA1c (clinicaltrials.gov/study/NCT04093752)

    Standard Error: 0.073 (clinicaltrials.gov)

    Overall outcome: 193 Participants (clinicaltrials.gov/study/NCT04093752) analyzed

    Outcome definition & treatment groups

    HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed model repeated measures (MMRM) model with covariates Baseline + Country + Baseline Oral Antihyperglycemic Medication (OAM) Use (Metformin (Met), Met plus Sulfonylurea (SU)) + Treatment + Time + Treatment\*Time (Type III sum of squares).

    10 mg Tirzepatide: Participants received 10 mg tirzepatide administered SC QW.

    15 mg Tirzepatide: Participants received 15 mg tirzepatide administered SC QW.

    Insulin Glargine: Participants received insulin glargine administered QD SC. The starting dose of insulin glargine was 6 IU/day at bedtime, titrated to a FBG between 72-100 mg/dL, following a TTT algorithm.

    One of 1 registered primary outcome, selected for its reported data and weight or blood-sugar endpoint where available. These are registry values; published analyses may differ. Full results on ClinicalTrials.gov (clinicaltrials.gov).

  • Primary outcome: Percent Change From Randomization in Body Weight at Week 88

    Selected primary outcome

    Results · Oct 15, 2026 UTC

    Percent Change From Randomization in Body Weight at Week 88

    Least-squares mean · percent change · Randomization (Week 36), Week 88

    Analysis population: All randomized participants who received at least one dose of the study drug, had randomization and at least one post-randomization values for this outcome, excluding data after discontinuation of the study drug.

    Placebo
    14.8 percent change (clinicaltrials.gov/study/NCT04660643)

    Standard Error: 0.53 (clinicaltrials.gov)

    Overall outcome: 329 Participants (clinicaltrials.gov/study/NCT04660643) analyzed

    Tirzepatide MTD
    -6.7 percent change (clinicaltrials.gov/study/NCT04660643)

    Standard Error: 0.52 (clinicaltrials.gov)

    Overall outcome: 332 Participants (clinicaltrials.gov/study/NCT04660643) analyzed

    Outcome definition & treatment groups

    Least square (LS) mean was analysed by mixed model repeated measures (MMRM) model with randomization + analysis country + sex + interactive web response system (IWRS) MTD at Week 36 + treatment + time + treatment\*time (Type III sum of squares) as variables.

    Placebo: Participants received weekly doses of placebo SC for 52 weeks.

    Tirzepatide MTD: Participants continued tirzepatide MTD (either 10 mg or 15 mg) for an additional 52 weeks.

    One of 1 registered primary outcome, selected for its reported data and weight or blood-sugar endpoint where available. These are registry values; published analyses may differ. Full results on ClinicalTrials.gov (clinicaltrials.gov).

  • Primary outcome: Change From Baseline in the Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS)

    Selected primary outcome

    Results · Nov 3, 2026 UTC

    Change From Baseline in the Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS)

    Least-squares mean · Score on a scale · Baseline, Week 52

    Analysis population: All participants who received at least one dose of study drug and had evaluable data for this outcome.

    Tirzepatide - MTD
    19.51 Score on a scale (clinicaltrials.gov/study/NCT04847557)

    Standard Error: 1.24 (clinicaltrials.gov)

    Overall outcome: 301 Participants (clinicaltrials.gov/study/NCT04847557) analyzed

    Placebo
    12.68 Score on a scale (clinicaltrials.gov/study/NCT04847557)

    Standard Error: 1.25 (clinicaltrials.gov)

    Overall outcome: 313 Participants (clinicaltrials.gov/study/NCT04847557) analyzed

    Outcome definition & treatment groups

    The KCCQ is a 23-item, participant self-administered questionnaire that assesses impacts of heart failure "over the past 2 weeks" on the following 7 domains: * Physical Limitation (6) * Symptom Stability (1) * Symptom Frequency (4) * Symptom Burden (3) * Self-Efficacy (2) * Quality of Life (3) * Social Limitation (4) Each of the 23 individual items are answered on Likert scales of varying lengths (5, 6, or 7-point scales). KCCQ-CSS includes the symptom and physical limitation domains of the KCCQ. Scores are obtained by averaging the associated individual items and transforming the score to a 0 to 100 range. Higher scores indicate better health status. Least Square (LS) mean was determined using ANCOVA model with Baseline + HF Decompensation Within 12 Months of Screening + T2DM Status + Baseline BMI group (\<35, \>=35 kg/m2) + Treatment (Type III sum of squares) as variables .

    Tirzepatide - MTD: Participants received a starting dose of 2.5 mg tirzepatide administered SC QW and escalated by 2.5 mg every 4 weeks to a maximum of 15 mg QW or MTD tolerated by the participant (5 mg QW or 10 mg QW).

    Placebo: Participants received placebo administered SC QW.

    One of 2 registered primary outcomes, selected for its reported data and weight or blood-sugar endpoint where available. These are registry values; published analyses may differ. Full results on ClinicalTrials.gov (clinicaltrials.gov).

  • Primary outcome: Change From Baseline in Hemoglobin A1c (HbA1c)

    Selected primary outcome

    Results · Nov 3, 2026 UTC

    Change From Baseline in Hemoglobin A1c (HbA1c)

    Least-squares mean · percentage of HbA1c · Baseline, Week 52

    Analysis population: All randomized participants who received at least 1 dose of study drug and had a baseline and at least 1 post-baseline value, excluding data after initiating rescue antihyperglycemic medication or prematurely stopping study drug.

    5 mg Tirzepatide
    -2.37 percentage of HbA1c (clinicaltrials.gov/study/NCT03861052)

    Standard Error: 0.066 (clinicaltrials.gov)

    Overall outcome: 158 Participants (clinicaltrials.gov/study/NCT03861052) analyzed

    10 mg Tirzepatide
    -2.55 percentage of HbA1c (clinicaltrials.gov/study/NCT03861052)

    Standard Error: 0.067 (clinicaltrials.gov)

    Overall outcome: 156 Participants (clinicaltrials.gov/study/NCT03861052) analyzed

    15 mg Tirzepatide
    -2.82 percentage of HbA1c (clinicaltrials.gov/study/NCT03861052)

    Standard Error: 0.066 (clinicaltrials.gov)

    Overall outcome: 159 Participants (clinicaltrials.gov/study/NCT03861052) analyzed

    0.75 mg Dulaglutide
    -1.29 percentage of HbA1c (clinicaltrials.gov/study/NCT03861052)

    Standard Error: 0.065 (clinicaltrials.gov)

    Overall outcome: 159 Participants (clinicaltrials.gov/study/NCT03861052) analyzed

    Outcome definition & treatment groups

    HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model for post-baseline measures: Variable = Baseline + Baseline BMI Group (\<25 or \>=25 kg/m\^2) + Washout of Antidiabetic Medication + Treatment + Time + Treatment\*Time (Type III sum of squares).

    5 mg Tirzepatide: Participants received 5 mg tirzepatide administered SC once weekly for 52 weeks.

    10 mg Tirzepatide: Participants received 10 mg tirzepatide administered SC once weekly for 52 weeks.

    15 mg Tirzepatide: Participants received 15 mg tirzepatide administered SC once weekly for 52 weeks.

    0.75 mg Dulaglutide: Participants received 0.75 mg dulaglutide administered SC once weekly for 52 weeks

    One of 1 registered primary outcome, selected for its reported data and weight or blood-sugar endpoint where available. These are registry values; published analyses may differ. Full results on ClinicalTrials.gov (clinicaltrials.gov).

  • Primary outcome: Percent Change From Baseline in Body Weight

    Selected primary outcome

    Results · Nov 2, 2026 UTC

    Percent Change From Baseline in Body Weight

    Least-squares mean · Percent change · Baseline, 72 Weeks

    Analysis population: All randomly assigned participants who took at least 1 dose of study drug, had a baseline and at least 1 post- baseline value for this outcome, excluding data after discontinuation of study drug.

    Placebo
    3.3 Percent change (clinicaltrials.gov/study/NCT04657016)

    Standard Error: 0.60 (clinicaltrials.gov)

    Overall outcome: 291 Participants (clinicaltrials.gov/study/NCT04657016) analyzed

    Tirzepatide
    -21.1 Percent change (clinicaltrials.gov/study/NCT04657016)

    Standard Error: 0.59 (clinicaltrials.gov)

    Overall outcome: 284 Participants (clinicaltrials.gov/study/NCT04657016) analyzed

    Outcome definition & treatment groups

    Percent change from baseline in body weight. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares).

    Placebo: Participants received matching placebo SC once weekly QW.

    Tirzepatide: Participants received weekly doses of tirzepatide SC for 72 weeks, starting at 2.5 mg for 4 weeks. Subsequently, the dose was increased by 2.5 mg every 4 weeks up to the MTD of either 10 mg or 15 mg.

    One of 2 registered primary outcomes, selected for its reported data and weight or blood-sugar endpoint where available. These are registry values; published analyses may differ. Full results on ClinicalTrials.gov (clinicaltrials.gov).

  • Primary outcome: Change From Baseline in Hemoglobin A1c (HbA1c)

    Selected primary outcome

    Results · Oct 5, 2026 UTC

    Change From Baseline in Hemoglobin A1c (HbA1c)

    Least-squares mean · Percentage of HbA1c · Baseline, Week 40

    Analysis population: All randomized participants who received at least 1 dose of study drug and had a baseline and at least 1 post-baseline value, excluding patients discontinuing study drug due to inadvertent enrollment and data after initiating rescue antihyperglycemic medication or prematurely stopping study drug.

    5 mg Tirzepatide
    -1.87 Percentage of HbA1c (clinicaltrials.gov/study/NCT03954834)

    Standard Error: 0.094 (clinicaltrials.gov)

    Overall outcome: 121 Participants (clinicaltrials.gov/study/NCT03954834) analyzed

    10 mg Tirzepatide
    -1.89 Percentage of HbA1c (clinicaltrials.gov/study/NCT03954834)

    Standard Error: 0.096 (clinicaltrials.gov)

    Overall outcome: 118 Participants (clinicaltrials.gov/study/NCT03954834) analyzed

    15 mg Tirzepatide
    -2.07 Percentage of HbA1c (clinicaltrials.gov/study/NCT03954834)

    Standard Error: 0.098 (clinicaltrials.gov)

    Overall outcome: 116 Participants (clinicaltrials.gov/study/NCT03954834) analyzed

    Placebo
    0.04 Percentage of HbA1c (clinicaltrials.gov/study/NCT03954834)

    Standard Error: 0.105 (clinicaltrials.gov)

    Overall outcome: 112 Participants (clinicaltrials.gov/study/NCT03954834) analyzed

    Outcome definition & treatment groups

    HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with Baseline + Pooled Country + Prior Use of oral antihyperglycemic medication (OAM) (Yes, No) + Treatment + Time + Treatment\*Time (Type III sum of squares).

    5 mg Tirzepatide: Participants received 5 mg of tirzepatide as subcutaneous injection once a week.

    10 mg Tirzepatide: Participants received 10mg of tirzepatide as subcutaneous injection once a week.

    15 mg Tirzepatide: Participants received 15mg of tirzepatide as subcutaneous injection once a week.

    Placebo: Participants received placebo as subcutaneous injection once a week.

    One of 1 registered primary outcome, selected for its reported data and weight or blood-sugar endpoint where available. These are registry values; published analyses may differ. Full results on ClinicalTrials.gov (clinicaltrials.gov).

Source: ClinicalTrials.gov API v2 (clinicaltrials.gov/search) · as of Nov 17, 2026

All trials on ClinicalTrials.gov (clinicaltrials.gov)
FDA enforcement archive

Recall records

Enforcement records describe specific recalled products and lots. They do not establish the recall status of every product containing the ingredient. openFDA does not maintain current recall status after classification; read the FDA record and any manufacturer notice for details.

28 indexed product records, ordered by FDA report date. One recall event may include several products.

D-0040-2027

Class IIFDA report: Oct 21, 2026

Recalling firm: Houston Rx LLC

Tirzepatide/Niacinamide 2mL vial (40 MG per Vial) Inj 20mg/2mg/mL, RX Only, Houston RX LLC, 15430 Vantage Parkway E STE 220, Houston, TX 77032.

Reason for recall

Lack of assurance of sterility.

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0017-2027

Class IIFDA report: Oct 14, 2026

Recalling firm: Carolina Infusion, LLC

TIRZEPATIDE 26 MG/ML INJECTABLE, Packaged in single-use dosage syringes, total mL dispensed based on dosage per specific patient prescription, Carolina Infusion LLC, 95 Bees Creek Road, Ridgeland, SC 29936;

Reason for recall

Lack of Assurance of Sterility: Related to formulation using bacteriostic water; Related to processing equipment used in compounded product.

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0027-2027

Class IIFDA report: Oct 14, 2026

Recalling firm: Carolina Infusion, LLC

TIRZEPATIDE/CYANOCOBALAMIN 26/2 MG/ML INJECTABLE, Packaged in single-use dosage syringes, total mL dispensed based on dosage per specific patient prescription, Carolina Infusion LLC, 95 Bees Creek Road, Ridgeland, SC 29936

Reason for recall

Lack of Assurance of Sterility: Related to formulation using bacteriostic water; Related to processing equipment used in compounded product.

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0028-2027

Class IIFDA report: Oct 14, 2026

Recalling firm: Carolina Infusion, LLC

TIRZEPATIDE/CYANOCOBALAMIN 64/2 MG/ML INJECTABLE, Packaged in single-use dosage syringes, total mL dispensed based on dosage per specific patient prescription, Carolina Infusion LLC, 95 Bees Creek Road, Ridgeland, SC 29936

Reason for recall

Lack of Assurance of Sterility: Related to formulation using bacteriostic water; Related to processing equipment used in compounded product.

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0029-2027

Class IIFDA report: Oct 14, 2026

Recalling firm: Carolina Infusion, LLC

TIRZEPATIDE/CYANOCOBALAMIN 76/2 MG/ML INJECTABLE, Packaged in single-use dosage syringes, total mL dispensed based on dosage per specific patient prescription, Carolina Infusion LLC, 95 Bees Creek Road, Ridgeland, SC 29936

Reason for recall

Lack of Assurance of Sterility: Related to formulation using bacteriostic water; Related to processing equipment used in compounded product.

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0030-2027

Class IIFDA report: Oct 14, 2026

Recalling firm: Carolina Infusion, LLC

TIRZEPATIDE/CYANOCOBALAMIN 85/2 MG/ML INJECTABLE, Packaged in single-use dosage syringes, total mL dispensed based on dosage per specific patient prescription, Carolina Infusion LLC, 95 Bees Creek Road, Ridgeland, SC 29936;

Reason for recall

Lack of Assurance of Sterility: Related to formulation using bacteriostic water; Related to processing equipment used in compounded product.

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026
More indexed recall records (22)

D-0036-2027

Class IIFDA report: Oct 14, 2026

Recalling firm: Apothecary Pharma LLC

Tirzepatide Injection, 18mg/mL, 4 mL Sterile Multi-Dose Vial, Rx only, Apothecary Pharma, LLC, 1913 Evans Road, Cary, NC 27513, NDC 85091-001-18.

Reason for recall

Lack of Assurance of Sterility

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0394-2026

Class IIFDA report: Mar 11, 2026

Recalling firm: New Life Pharma LLC

Tirzepatide Inj, 10mg, Sterile Multi-Dose Vial, Rx only, Nomida, 25055 W Valley Pkwy, Suite 106, Olathe, KS 66061, NDC 84223-002-03.

Reason for recall

Lack of Assurance of Sterility

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0395-2026

Class IIFDA report: Mar 11, 2026

Recalling firm: New Life Pharma LLC

Tirzepatide Inj, 15mg x 4, Sterile Multi-Dose Vial, Rx only, Nomida, 25055 W Valley Pkwy, Suite 106, Olathe, KS 66061, NDC 84223-002-04.

Reason for recall

Lack of Assurance of Sterility

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0120-2026

Class IIFDA report: Nov 5, 2025

Recalling firm: ProRx LLC

Tirzepatide Injection, 27 mg/3 mL (9 mg/mL), 3mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84139-209-03

Reason for recall

Lack of Assurance of Sterility

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0092-2026

Class IIFDA report: Oct 15, 2025

Recalling firm: GenoGenix LLC

Tirzepatide, 60mg/10 mL for Injection, 10mL vial lyophilized, all presentations, GenoGenix, LLC, 2840 NW 2nd Ave Ste 204 Boca Raton, FL 33431-6692. Also labeled as manufactured for Extension Health and Synergy Wellness 60mg, 10mL vial lyophilized.

Reason for recall

Lack of Assurance of Sterility

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0554-2025

Class IIFDA report: Aug 13, 2025

Recalling firm: AEQUITA PHARMACY

Tirzepatide + Niacinamide 2.2 mg + 1.0mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034.

Reason for recall

Lack of Processing Controls.

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0555-2025

Class IIFDA report: Aug 13, 2025

Recalling firm: AEQUITA PHARMACY

Tirzepatide + Niacinamide 4.4 mg + 1.0mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034.

Reason for recall

Lack of Processing Controls.

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0556-2025

Class IIFDA report: Aug 13, 2025

Recalling firm: AEQUITA PHARMACY

Tirzepatide + Niacinamide 6.6 mg + 1.0mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034.

Reason for recall

Lack of Processing Controls.

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0557-2025

Class IIFDA report: Aug 13, 2025

Recalling firm: AEQUITA PHARMACY

Tirzepatide + Niacinamide 8.8 mg + 1.0mg/0.5 ml Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034.

Reason for recall

Lack of Processing Controls.

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0558-2025

Class IIFDA report: Aug 13, 2025

Recalling firm: AEQUITA PHARMACY

Tirzepatide + Niacinamide 11.24 mg + 1.0mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034.

Reason for recall

Lack of Processing Controls.

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0559-2025

Class IIFDA report: Aug 13, 2025

Recalling firm: AEQUITA PHARMACY

Tirzepatide + Niacinamide 13.2 mg + 1.0mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034.

Reason for recall

Lack of Processing Controls.

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0560-2025

Class IIFDA report: Aug 13, 2025

Recalling firm: AEQUITA PHARMACY

Tirzepatide + Niacinamide 16.6 mg + 1.0mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 3 x 2 mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034.

Reason for recall

Lack of Processing Controls.

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0482-2025

Class IIFDA report: Jul 2, 2025

Recalling firm: Thrive Health and Wellness, LLC, dba Thrive Health Solutions (Colorado)

Tirzepatide Injections, 10mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewood, CO 80112

Reason for recall

Lack of Assurance of Sterility

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0483-2025

Class IIFDA report: Jul 2, 2025

Recalling firm: Thrive Health and Wellness, LLC, dba Thrive Health Solutions (Colorado)

Tirzepatide Injections, 20mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewood, CO 80112

Reason for recall

Lack of Assurance of Sterility

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0484-2025

Class IIFDA report: Jul 2, 2025

Recalling firm: Thrive Health and Wellness, LLC, dba Thrive Health Solutions (Colorado)

Tirzepatide Injections, 30mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewood, CO 80112

Reason for recall

Lack of Assurance of Sterility

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0485-2025

Class IIFDA report: Jul 2, 2025

Recalling firm: Thrive Health and Wellness, LLC, dba Thrive Health Solutions (Colorado)

Tirzepatide/Cyanocobalamin Injectable, 15mg/1mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewood, CO 80112

Reason for recall

Lack of Assurance of Sterility

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0486-2025

Class IIFDA report: Jul 2, 2025

Recalling firm: Thrive Health and Wellness, LLC, dba Thrive Health Solutions (Colorado)

Tirzepatide/Cyanocobalamin Injectable, 30mg/1mg/mL (15mg/0.5mg/0.5mL), pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewood, CO 80112

Reason for recall

Lack of Assurance of Sterility

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0651-2024

Class IIFDA report: Sep 11, 2024

Recalling firm: ProRx LLC

Tirzepatide 2 mL (10 mg/mL) and 20 mg/mL, 2mL Multidose SC Injection vials, Compounded Rx Product, ProRx 267-565-7008, NDC 84139-210-01

Reason for recall

Lack of Assurance of Sterility

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0655-2024

Class IIFDA report: Sep 11, 2024

Recalling firm: ProRx LLC

TIRZEPATIDE 20 mg/2mL (10/mg/mL), Rx Only, 2mL Multiple Dose Vial, Mfd by: ProRx Exton, PA, 19341, NDC 84139-210-01

Reason for recall

Lack of Assurance of Sterility

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0656-2024

Class IIFDA report: Sep 11, 2024

Recalling firm: ProRx LLC

TIRZEPATIDE 60 mg/3mL (20/mg/mL), Rx Only, 3mL Multiple Dose Vial, Mfd by: ProRx Exton, PA, 19341, NDC 84139-210-02

Reason for recall

Lack of Assurance of Sterility

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0511-2024

Class IFDA report: Jun 5, 2024

Recalling firm: Revive Rx LLC dba Revive Rx Pharmacy

Tirzepatide 10 mg/0.5 mL Sterile Solution, 2 mL Multi-dose vial, Rx only, This is a Compounded Product By: Revive RX Pharmacy, 3831 Golf Dr A, Houston, TX 77018, internally assigned NDC 99000-9278-64

Reason for recall

Labeling: Label Mix-up - product labeled as tirzepatide contains testosterone cypionate

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

D-0771-2023

Class IIFDA report: May 31, 2023

Recalling firm: Revive Rx LLC dba Revive Rx Pharmacy

Tirzepatide 10 mg/0.5 mL Sterile Solution-2 mL Vial, Rx Only, For Sub-Q Use Only, Compounded Drug Product By: Revive Rx, 3831 Golf Dr A, Houston, TX 77018, NDC: 99000-9278-64.

Reason for recall

Sub-potent Drug

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

Browse the FDA enforcement archive (accessdata.fda.gov) · Source coverage & limitations (open.fda.gov)

Compounded tirzepatide is not an FDA-approved product and is not reviewed by the FDA for safety, effectiveness, or quality. The FDA declared the tirzepatide shortage resolved in December 2024, which ended the exemption that let pharmacies make copies of the approved drug in bulk. FDA (fda.gov) (FDA: policies for compounders as the GLP-1 supply stabilizes) Compounded tirzepatide prices from every seller we track.
Related

Related GLP-1s to compare

Updated automatically

What changed for Tirzepatide

  • PricePrice no longer listed: tirzepatide via primma wellness at primmawellness (was Product price not verified)
  • PriceNew price listed: Zappy Health, Zappy Health membership (brand GLP-1 care), $99/mo (read on zappyhealth.com)
  • PriceNew price listed: Nucific, Zepbound via Nucific, from $1,828/mo (read on nucific.com)
  • PriceSeller listed without a price we compare: Invigor Medical, Compounded tirzepatide sublingual via Invigor Medical (Product price not verified) (read on tryinvigor.com)
  • PriceNew price listed: OurHealth Rx, Compounded tirzepatide via OurHealth Rx, $399/4 weeks (read on ourhealthrx.com)
  • PriceNew price listed: LeanDreams, Tirzepatide via LeanDreams, from $399/mo (read on shop.leandreamsweightloss.com)
  • PriceNew price listed: Primma Wellness, Compounded tirzepatide via Primma Wellness, $349/mo (read on primmawellness.com)
  • PriceProtocol MD: Compounded tirzepatide via Protocol MD now $299/mo (was $319/mo) (read on protocolmd.com)

Written from each source's own record as it changes. Every change on GLPcompare

ClinicalTrials.gov

What Tirzepatide is studied for

Registered trials of this medicine by condition. A trial shows a question being asked, not that the answer is yes.

From PubMed

Latest Tirzepatide trials and reviews

  • Tirzepatide in Adolescents With Obesity: The SURMOUNT-ADOLESCENTS Randomized Clinical Trial (pubmed.ncbi.nlm.nih.gov/43035096)

    Randomized trial · JAMA · Nov 15, 2026 · Kelly AS et al.

  • Kidney effects of tirzepatide across albuminuria, filtration markers, and clinical outcomes: a parent-trial-level systematic review and meta-analysis (pubmed.ncbi.nlm.nih.gov/43025465)

    Meta-analysis · Diabetes Res Clin Pract · Nov 13, 2026 · Li S et al.

  • Durable and Additive Disease Control at 52 Weeks With Ixekizumab Plus Tirzepatide Versus Ixekizumab Alone in Adults With Psoriatic Arthritis and Obesity or Overweight: Additional Results From a Randomized Clinical Trial (pubmed.ncbi.nlm.nih.gov/43012507)

    Randomized trial · Arthritis Rheumatol · Nov 11, 2026 · Merola JF et al.

  • Resistance exercise to attenuate lean mass loss during tirzepatide therapy for obesity: a randomized controlled trial (pubmed.ncbi.nlm.nih.gov/43003902)

    Randomized trial · Nat Med · Nov 9, 2026 · Green DJ et al.

  • Longitudinal Taxonomic and Predicted Functional Gut Microbiome Responses to Tirzepatide and Semaglutide: An Exploratory Secondary Analysis of the OMDOT-1 Randomized Controlled Trial (pubmed.ncbi.nlm.nih.gov/43000189)

    Randomized trial · Diabetes Obes Metab · Nov 8, 2026 · Morioka T et al.

  • Effects of tirzepatide (GIP/GLP-1 dual receptor agonist) on cardiorenal biomarkers and functional capacity in heart failure: a systematic review and meta-analysis (pubmed.ncbi.nlm.nih.gov/42867450)

    Meta-analysis · J Clin Endocrinol Metab · Oct 13, 2026 · Eisa N et al.

  • Cutaneous Adverse Events Associated with Semaglutide, Liraglutide and Tirzepatide: A Systematic Review (pubmed.ncbi.nlm.nih.gov/42930571)

    Systematic review · Med Sci (Basel) · Oct 9, 2026 · Gupta AK et al.

  • Comparative Efficacy of Tirzepatide Versus Semaglutide for Weight Loss in Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis of Head-to-Head Studies (pubmed.ncbi.nlm.nih.gov/42670242)

    Meta-analysis · Clin Obes · Oct 1, 2026 · Paccola GP et al.

Listed from Europe PMC as published, newest first. A listing here is not a judgement of a study's quality or a recommendation.

Questions

Common questions about Tirzepatide

What is the brand name of tirzepatide?
Tirzepatide is sold in the US as Mounjaro and Zepbound. A compounded version has no brand name and is not FDA-approved.
Is Tirzepatide in shortage?
No matching shortage record was returned in the latest complete FDA check. Last complete check: Nov 17, 2026. Confirm local stock with your pharmacy. Source (accessdata.fda.gov)
Is there a generic tirzepatide?
No. FDA has not approved a generic of Mounjaro. No. FDA has not approved a generic of Zepbound. Source
How much does Tirzepatide cost per month?
Among the sourced FDA-approved offers in our catalog, a tracked starting quote is $299/28 days for Zepbound KwikPen via Amazon Pharmacy via Amazon Pharmacy. ≈ $320.36 per 30 days at this quoted rate. without insurance, 2.5 mg; includes the manufacturer coupon if eligible (list price $498.98); prescription required The 7.5 mg KwikPen is also $449. Amazon fills a prescription you already have and delivers in all 50 states. FDA-approved product. 28-day supply The quote at the cited trial dose is $449/28 days for Zepbound KwikPen via Amazon Pharmacy at 15 mg via Amazon Pharmacy. without insurance, with Lilly's self-pay card, which ends 12/31/2026 and requires each refill within 45 days of the previous delivery, as Lilly's Zepbound savings page states (otherwise Lilly's regular $699); 15 mg; includes the manufacturer coupon if eligible (list price $699) The 7.5 mg KwikPen is also $449. Amazon fills a prescription you already have and delivers in all 50 states. FDA-approved product. 28-day supply Starting and trial-dose quotes may cover different products. These are self-pay offers, not insurance estimates or a guarantee of eligibility. Source (pharmacy.amazon.com)
How much weight can you lose on Tirzepatide?
In its pivotal trial (SURMOUNT-1), Tirzepatide at 15 mg weekly (Zepbound) showed a mean body-weight change of -20.9% at 72 wks. This is a trial average; individual results vary. Source (nejm.org)
What is Tirzepatide approved for?
Approved uses across Tirzepatide products include type 2 diabetes, chronic weight management, obstructive sleep apnea with obesity and cardiovascular risk reduction. Indications differ by brand and formulation; this does not mean every product is approved for every use. See the product-specific prescribing information above.